<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Discov Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Discov Oncol</journal-id><journal-id journal-id-type="pmc-domain-id">4139</journal-id><journal-id journal-id-type="pmc-domain">discon</journal-id><journal-title-group><journal-title>Discover Oncology</journal-title></journal-title-group><issn pub-type="epub">2730-6011</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12748365</article-id><article-id pub-id-type="pmcid-ver">PMC12748365.1</article-id><article-id pub-id-type="pmcaid">12748365</article-id><article-id pub-id-type="pmcaiid">12748365</article-id><article-id pub-id-type="pmid">41261346</article-id><article-id pub-id-type="doi">10.1007/s12672-025-04100-y</article-id><article-id pub-id-type="publisher-id">4100</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Multi-omics analysis reveals PIAS family gene dysregulation as a driver of head and neck squamous cell carcinoma (HNSC) progression and therapeutic vulnerability</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hussain</surname><given-names initials="M">Mumtaz</given-names></name><address><email>mumtazdr2005@yahoo.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ishfaq</surname><given-names initials="M">Mehreen</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hameed</surname><given-names initials="SA">Syeda Amber</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abbas</surname><given-names initials="AS">Afshan Syed</given-names></name><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Bhanbhro</surname><given-names initials="MUR">Mujeeb ur Rehman</given-names></name><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ain</surname><given-names initials="QU">Qurat ul</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Abdel-Maksoud</surname><given-names initials="MA">Mostafa A.</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Alamri</surname><given-names initials="A">Abdulaziz</given-names></name><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almutairi</surname><given-names initials="S">Saeedah</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almanaa</surname><given-names initials="TN">Taghreed N.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ayaz</surname><given-names initials="MM">Muhammad Mazhar</given-names></name><address><email>mmazharayaz@cuvas.edu.pk</email></address><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Hameed</surname><given-names initials="Y">Yasir</given-names></name><address><email>yasirhameed2011@gmail.com</email></address><xref ref-type="aff" rid="Aff10">10</xref><xref ref-type="aff" rid="Aff11">11</xref></contrib><aff id="Aff1"><label>1</label>Department of Anatomy, Peoples University of Medical &amp; Health Sciences Nawabshah, Nawabshah, Pakistan </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05h1kgg64</institution-id><institution-id institution-id-type="GRID">grid.416754.5</institution-id><institution-id institution-id-type="ISNI">0000 0004 0607 6073</institution-id><institution>Integerated Disease Survillence and Response System (IDSRS), </institution><institution>National Institute of Health (NIH), Chak Shahzad, </institution></institution-wrap>Islamabad, Pakistan </aff><aff id="Aff3"><label>3</label>Department of Biological and Environmental Sciences, Emerson University, Multan, Pakistan </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/052z7nw84</institution-id><institution-id institution-id-type="GRID">grid.440554.4</institution-id><institution-id institution-id-type="ISNI">0000 0004 0609 0414</institution-id><institution>University of Education, </institution></institution-wrap>Bank Road Campus, Lahore, Pakistan </aff><aff id="Aff5"><label>5</label>Anatomy Department, Gambat Medical College, Gambat, Pakistan </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f81g417</institution-id><institution-id institution-id-type="GRID">grid.56302.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1773 5396</institution-id><institution>Research Chair of Biomedical Applications of Nanomaterials, Biochemistry Department, </institution><institution>College of Science, King Saud University, </institution></institution-wrap>Riyadh, Saudi Arabia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f81g417</institution-id><institution-id institution-id-type="GRID">grid.56302.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1773 5396</institution-id><institution>Botany and Microbiology Department, College of Science, </institution><institution>King Saud University, </institution></institution-wrap>Riyadh, Saudi Arabia </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02f81g417</institution-id><institution-id institution-id-type="GRID">grid.56302.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1773 5396</institution-id><institution>Botany and Microbiology Department, College of Science, </institution><institution>King Saud University, </institution></institution-wrap>Riyadh, Saudi Arabia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00g325k81</institution-id><institution-id institution-id-type="GRID">grid.412967.f</institution-id><institution-id institution-id-type="ISNI">0000 0004 0609 0799</institution-id><institution>Department of Parasitology, </institution><institution>Cholistan University of Veterinary and Animal Sciences Bahawalpur Pakistan, </institution></institution-wrap>Bahawalpur, Pakistan </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/002rc4w13</institution-id><institution-id institution-id-type="GRID">grid.412496.c</institution-id><institution-id institution-id-type="ISNI">0000 0004 0636 6599</institution-id><institution>Department of Biochemistry and Biotechnology, </institution><institution>The Islamia University of Bahawalpur, </institution></institution-wrap>Bahawalpur, Pakistan </aff><aff id="Aff11"><label>11</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/05sj3n476</institution-id><institution-id institution-id-type="GRID">grid.143643.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0660 6861</institution-id><institution>Department of Applied Biological Sciences, </institution><institution>Tokyo University of Science, </institution></institution-wrap>Tokyo, Japan </aff></contrib-group><pub-date pub-type="epub"><day>20</day><month>11</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>12</month><year>2025</year></pub-date><volume>16</volume><issue-id pub-id-type="pmc-issue-id">478248</issue-id><elocation-id>2247</elocation-id><history><date date-type="received"><day>22</day><month>4</month><year>2025</year></date><date date-type="accepted"><day>13</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>20</day><month>11</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>31</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-12-31 00:25:13.470"><day>31</day><month>12</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="12672_2025_Article_4100.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Head and neck squamous cell carcinoma (HNSC) stand as one of the most fatal malignancies worldwide. The intricate nature of this disease has contributed to a limited understanding of its diagnostic and prognostic indicators. This study comprehensively investigated the dysregulation of PIAS family genes (PIAS1, PIAS2, PIAS3, and PIAS4) in Head and Neck Squamous Cell Carcinoma (HNSC).</p></sec><sec><title>Methods</title><p id="Par2">Cell culturing, RT-qPCR, bisulfite sequencing, UALCAN, GEPIA, Human Protein Atlas (HPA), MEXPRESS, cBioPortal, Prognostic model development, DAVID, TISCH2, cell culture, gene knockdown, cell culture, colony formation, wound healing, DrugBank, and molecular docking analyses.</p></sec><sec><title>Results</title><p id="Par3">RT-qPCR demonstrated significant up-regulation of PIAS1, PIAS2, PIAS3, and PIAS4 in HNSC cell lines. ROC curve analysis indicated high diagnostic accuracy for these genes. Promoter methylation analysis revealed a negative correlation, suggesting hypomethylation as a potential mechanism for their overexpression. Validation across multiple datasets and immunohistochemistry supported their up-regulation in HNSC. Mutational analysis showed low mutation frequencies in PIAS1, PIAS2, PIAS3, and PIAS4 genes. Survival analysis implicated elevated PIAS expression in poorer overall survival of HNSC patients, and a prognostic model demonstrated predictive robustness. Correlation with immune cells highlighted associations of PIAS gene with various immune cell types. GO and KEGG analyses unveiled functional involvement of PIAS genes in critical cellular processes and signaling pathways. Functional assays demonstrated that PIAS knockdown inhibited HNSC cell proliferation, migration, and invasion. Lastly, the identification of Cyclocreatine and Vorinostat as potential inhibitors through drug acquisition and molecular docking provides insights into therapeutic avenues for HNSC patients.</p></sec><sec><title>Conclusion</title><p id="Par4">These findings contribute to the understanding of PIAS family genes in HNSC pathogenesis, diagnosis, prognosis, and potential therapeutic targeting.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s12672-025-04100-y.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HNSC</kwd><kwd>PIAS family genes</kwd><kwd>Diagnosis</kwd><kwd>Prognosis</kwd><kwd>Treatment</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100020912</institution-id><institution>King Faisal University</institution></institution-wrap></funding-source><award-id>ORF-2025-552</award-id><principal-award-recipient><name name-style="western"><surname>Abdel-Maksoud</surname><given-names>Mostafa A.</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media LLC, part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par5">Head and Neck Squamous Cell Carcinoma (HNSC) constitute a group of malignancies that affect the mucosal linings of the upper aerodigestive tract, encompassing regions such as the oral cavity, pharynx, and larynx [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. In some regions, particularly Southeast Asia, the incidence of HNSC is notably high. Conversely, in other parts of the world, such as North America and parts of Europe, the rise in oropharyngeal cancers linked to HPV infection has contributed to changing epidemiological patterns [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR6">6</xref>]. Other risk factors for HNSC are diverse and include tobacco and alcohol consumption, as well as exposure to environmental carcinogens [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. The manifestation of HNSC often involves localized symptoms such as difficulty in swallowing, persistent hoarseness, and the presence of pain or lumps in the affected regions [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. Despite advancements in cancer research, the need for identifying diagnostic biomarkers for HNSC remains imperative.</p><p id="Par6">The PIAS (Protein Inhibitor of Activated STAT) family genes, comprising PIAS1, PIAS2 (PIASx), PIAS3, and PIAS4 (PIASy), are integral regulators of cellular processes [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Primarily recognized for their role in modulating Signal Transducer and Activator of Transcription (STAT) signaling, PIAS proteins act as negative regulators, inhibiting STATs&#8217; DNA-binding activity and thus modulating gene expression [<xref ref-type="bibr" rid="CR15">15</xref>]. Beyond STAT signaling, PIAS proteins function as SUMO E3 ligases, participating in SUMOylation&#8212;a process influencing protein activity, localization, and stability [<xref ref-type="bibr" rid="CR16">16</xref>]. These proteins also serve as transcriptional regulators, impacting various transcription factors and contributing to cellular responses to stress, DNA damage, and immune functions [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Recently, the expression of PIAS family genes exhibits a close association with human diseases, notably cancer. For instance, the dysregulated expression of PIAS1 hampers the differentiation of liver cancer cells and serves as a diagnostic biomarker distinguishing colon cancer from adenomas [<xref ref-type="bibr" rid="CR19">19</xref>]. Moreover, PIAS1 emerges as a potential biomarker signifying susceptibility to stress [<xref ref-type="bibr" rid="CR20">20</xref>]. In various tumors, PIAS3 protein expression is notably elevated, spanning lung, colorectal, breast, and prostate cancers [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. PIAS4&#8217;s tight correlation with the onset and progression of specific human cancers, such as pancreatic and liver cancers, emphasize its significance [<xref ref-type="bibr" rid="CR23">23</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. Collectively, these findings underscore the broad involvement of PIAS family genes in diverse biological functions across various human cancers.</p><p id="Par7">In our investigation, we delved into the oncogenic implications, diagnostic and prognostic potentials, as well as the therapeutic aspects of PIAS family genes in HNSC through a multi-level approach, combining in silico analyses with molecular experiments [<xref ref-type="bibr" rid="CR25">25</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. Overall, this study provides a multi-dimensional perspective on the PIAS family genes in HNSC, revealing their complex role in oncogenesis, their potential as diagnostic and prognostic biomarkers, and their promise as therapeutic targets. The integration of bioinformatics analyses, molecular validation, and drug discovery strategies positions PIAS genes as a promising avenue for future HNSC research and potential clinical applications.</p></sec><sec id="Sec2"><title>Methodology</title><sec id="Sec3"><title>Cell culture</title><p id="Par8">A total of nine Human Nasopharyngeal Squamous Cell Carcinoma (HNSC) cell lines (FaDu, Detroit 562, SQUU-B, SCC-15, SCC-25, UPCI: SCC-131, UMSCC-22B, HN12, HN30) and nine Human Oral Keratinocyte (HOK) cell lines (HOK-16B, HOK-15B, NHOK, HOK-1, NOK, NOE, HOK-2B, HOK-3B, HOK-4B) were obtained from ATCC. HNSC cells were cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin, while HOK cells were maintained in Keratinocyte-SFM medium supplemented with 10% FBS and 1% penicillin-streptomycin. All cells were incubated at 37&#160;&#176;C in a humidified atmosphere containing 5% CO&#8322;. When cultures reached approximately 70&#8211;80% confluency, cells were passaged by aspirating the medium, washing with phosphate-buffered saline (PBS), and detaching cells with trypsin-EDTA for 5&#160;min. The enzymatic reaction was neutralized using complete culture medium, and cells were counted with a hemocytometer before seeding into fresh T-75 flasks. Cell line authentication was performed via short tandem repeat (STR) profiling to confirm identity against ATCC reference profiles.</p></sec><sec id="Sec4"><title>Nucleic acid extraction</title><p id="Par9">Genomic DNA was isolated using a phenol-chloroform organic extraction method [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], which separates DNA from other cellular components based on solubility differences. The extracted DNA was precipitated, washed, and resuspended in buffer. Total RNA was extracted using TRIzol reagent method [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. DNA and RNA purity and concentration were assessed by measuring absorbance ratios at 260/280 nm using a spectrophotometer, with an ideal ratio between 1.8 and 2.0 indicating minimal contamination.</p></sec><sec id="Sec5"><title>RT-qPCR analysis</title><p id="Par10">Total mRNA was reverse transcribed into cDNA using a commercially available RT cDNA Synthesis Kit. Reactions were carried out on a ViiA 7 Real-time PCR System (Applied Biosystems), with each sample being run in triplicate to ensure accuracy and reproducibility. The relative expression levels were determined using the 2<sup>&#916;&#916;CT</sup> method, a widely accepted approach for comparing gene expression levels between experimental and control groups. To amplify both the control gene GAPDH and the target genes, following primers were used.</p><p id="Par11">GAPDH-F 5&#8217;-ACCCACTCCTCCACCTTTGAC-3&#8217;,</p><p id="Par12">GAPDH-R 5&#8217;-CTGTTGCTGTAGCCAAATTCG-3&#8217;.</p><p id="Par13">PIAS1-F: 5&#8217;-TAAGGAGGATGGCACTTGGGCA-3&#8217;.</p><p id="Par14">PIAS1-R: 5&#8217;-TGAGACGCTACCTGATGCTCCA-3&#8217;.</p><p id="Par15">PIAS2-F: 5&#8217;-GTTCTTGGTGTCCAATGAGACCG-3&#8217;.</p><p id="Par16">PIAS2-R: 5&#8217;-TGCTTGCCTCACTGGCTACAGT-3&#8217;.</p><p id="Par17">PIAS3-F: 5&#8217;-ACTCTCAGCCACTGTTCCCAAC-3&#8217;.</p><p id="Par18">PIAS3-R: 5&#8217;-CAGTCAACTGCCTCACCAGGTA-3&#8217;.</p><p id="Par19">PIAS4-F: 5&#8217;-CCAACCGCATTACTGTCACCTG-3&#8217;.</p><p id="Par20">PIAS4-R: 5&#8217;-CGTCTTCAACCTCTGTAGCAGG-3&#8217;.</p></sec><sec id="Sec6"><title>Bisulfite sequencing</title><sec id="Sec7"><title>Library Preparation for targeted bisulfite sequencing analysis</title><p id="Par21">The DNA was fragmented, repaired, adenylated, and ligated with modified adapters before being quantified and sent to Beijing Genomic Institute (BGI), China, for targeted bisulfite sequencing. The raw methylation data were processed to calculate beta values, representing the proportion of methylated cytosines at each CpG site. Beta values were normalized using quantile normalization to reduce technical variability across samples. Probes with detection p-values greater than 0.01, those overlapping known single nucleotide polymorphisms (SNPs), and probes with low sequencing coverage were excluded to ensure high-quality data for downstream methylation analysis.</p></sec><sec id="Sec8"><title>Validation of PIAS family gene expression</title><p id="Par22">For the validation of mRNA expression of PIAS family genes, two online platforms, UALCAN [<xref ref-type="bibr" rid="CR32">32</xref>] and GEPIA2 [<xref ref-type="bibr" rid="CR33">33</xref>], were utilized to analyze TCGA datasets. The UALCAN server was used to evaluate the mRNA expression levels of the PIAS genes in HNSC samples and normal tissue controls. A total of 44 normal and 520 HNSC samples from TCGA were included in the analysis. The mRNA expression levels were then compared between the normal and HNSC groups. Additionally, GEPIA2, another web-based tool, was employed to further assess the mRNA expression of PIAS family genes in 44 healthy and 519 HNSC samples. Differential expression was determined using statistical tests embedded in these platforms, with significance defined by false discovery rate (FDR)-adjusted p-values &lt; 0.05. Additionally, fold-change thresholds of &#8805; 1.5 were applied to identify meaningful upregulation or downregulation of gene expression. To validate the protein expression of PIAS genes, immunohistochemistry (IHC) data were obtained from the HPA database [<xref ref-type="bibr" rid="CR34">34</xref>]. The IHC analysis was performed on available HNSC tissue samples to assess the levels of protein expression in cancerous tissues. The staining intensity of the target proteins was compared between HNSC tissues and normal tissue samples. The results were visualized through IHC staining images, and the protein expression levels were classified based on the observed staining intensities.</p></sec><sec id="Sec9"><title>Promoter methylation validation of PIAS family genes</title><p id="Par23">The promoter methylation levels of PIAS were validated in TCGA HNSC and normal tissue samples using the MEXPRESS platform [<xref ref-type="bibr" rid="CR35">35</xref>]. MEXPRESS allows for the analysis and visualization of DNA methylation data in relation to gene expression levels. The methylation data for the promoter regions of the PIAS family genes were obtained and compared between HNSC samples and normal tissue samples. The correlation between the promoter methylation levels and the corresponding gene expression levels was assessed.</p></sec><sec id="Sec10"><title>Mutational analysis of PIAS family genes</title><p id="Par24">The cBioPortal server [<xref ref-type="bibr" rid="CR36">36</xref>] was employed to investigate the mutations in PIAS family genes within HNSC samples. The mutational data was extracted from the TCGA HNSC dataset, which includes a total of 508 HNSC samples. The analysis was focused on identifying genetic alterations, including single nucleotide polymorphisms (SNPs) and missense mutations, in the promoter and coding regions of the PIAS family genes.</p></sec><sec id="Sec11"><title>Prognostic model development</title><p id="Par25">To assess the prognostic significance of PIAS family gene expression in HNSC, Kaplan-Meier survival analysis was performed using the Kaplan-Meier plotter tool [<xref ref-type="bibr" rid="CR37">37</xref>]. The analysis focused on determining the association between high expression levels of these genes and overall survival (OS) in HNSC patients.</p><p id="Par26">To construct a prognostic model based on the expression of PIAS family genes, the E_MTAB_8588 dataset was used as the training set, while the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE65858">GSE65858</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE75538">GSE75538</ext-link>, and TCGA_HNSC datasets were used for model validation. A stepwise Cox regression model was applied to identify the optimal set of predictors for overall survival. This model incorporated parameters such as hazard ratio (HR), c-index, and risk score to evaluate the prognostic value of the genes. The c-index was calculated to assess the model&#8217;s discriminative ability in predicting survival outcomes.</p></sec><sec id="Sec12"><title>Immune correlation</title><p id="Par27">The TISCH2 database [21] was employed to explore the correlation between the expression levels of PIAS family genes and various immune cells at the single-cell level. The HNSC_139324 dataset was selected in this study because it provides high-quality single-cell RNA-seq data specifically from HNSC samples with comprehensive immune cell annotation, enabling detailed analysis of tumor-immune interactions. The correlation between the expression of each PIAS gene and the immune cell populations was visualized using a matrix heat map.</p></sec><sec id="Sec13"><title>Gene enrichment analysis</title><p id="Par28">Gene enrichment analysis of the PIAS family genes was performed using the DAVID tool [<xref ref-type="bibr" rid="CR38">38</xref>]. This analysis involved Gene Ontology (GO) terms and KEGG pathway enrichment for the identified PIAS genes.</p></sec><sec id="Sec14"><title>Knockdown of PIAS family genes</title><p id="Par29">To knock down the PIAS family genes, siRNAs targeting PIAS1, PIAS2, PIAS3, and PIAS4 were obtained from OBiO Company. The FaDu cell lines were transfected with the specific siRNAs to silence the expression of the target genes. The transfection process was carried out using the INTERFERin Transfection Reagent (purchased from French), which was selected for its high efficiency in delivering small interfering RNA molecules into the cells. Following transfection, cells were incubated for an appropriate period to allow for siRNA-mediated gene silencing before proceeding with downstream analyses to evaluate the effects of the knockdown on gene expression and cellular functions.</p><p id="Par30">Western blot analysis was performed following the protocol outlined in a previous study. Briefly, protein extracts from cell lines were resolved by 11% SDS-PAGE, transferred to PVDF membranes, and blocked with 5% non-fat milk. The membranes were incubated overnight with primary antibodies targeting PIAS1, PIAS2, PIAS3, PIAS4, and &#946;-actin.</p></sec><sec id="Sec15"><title>Cell counting Kit-8 and colony formation assays</title><p id="Par31">The proliferation rate of FaDu cells was assessed using the Cell Counting Kit-8 (CCK-8) assay (APExBIO, USA). For this, 3&#8201;&#215;&#8201;10&#179; cells per well were seeded into 96-well plates 24&#160;h after transfection. The cells were incubated for different durations (0, 24, 48, and 72&#160;h). At each time point, CCK-8 reagent was added to each well, and the absorbance was measured at 450&#160;nm using a microplate reader to determine cell viability.</p><p id="Par32">For the colony formation assay, 5&#8201;&#215;&#8201;10&#178; FaDu cells were plated in 6-well plates and cultured for 10 days. The colonies were then fixed and stained with 0.1% crystal violet solution for 15&#160;min to visualize the colonies. The number of colonies was quantified using ImageJ software to assess the proliferative potential of the cells under different experimental conditions.</p></sec><sec id="Sec16"><title>Wound healing assay</title><p id="Par33">After transfection, FaDu cells were cultured in 6-well plates and allowed to reach approximately 80% confluence. A linear scratch was then created across the cell monolayer using a pipette tip to mimic a wound. Cell images were captured at two time points: 0&#160;h (immediately after wounding) and 24&#160;h post-wounding.</p></sec></sec><sec id="Sec17"><title>Molecular docking and molecular dynamics (MD) simulation analysis</title><sec id="Sec18"><title>Drugs acquisition</title><p id="Par34">The DrugBank database, a comprehensive pharmacological resource that compiles detailed information about drugs and their targets, was utilized in this study to predict potential inhibitors for PIAS family proteins. DrugBank provides extensive data on drug mechanisms, interactions, and adverse effects, offering valuable insights for researchers involved in drug discovery and development [<xref ref-type="bibr" rid="CR39">39</xref>]. In this study, we queried the DrugBank database to identify drugs that could potentially inhibit the activity of PIAS1, PIAS2, PIAS3, and PIAS4 proteins, based on their known interactions and molecular mechanisms.</p></sec><sec id="Sec19"><title>Ligand and receptor preparation</title><p id="Par35">To evaluate the binding affinities between Cyclocreatine, Vorinostat, and the PIAS family proteins, we performed molecular docking using the CB-DOCK web server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clab.labshare.cn/cb-dock/php/">http://clab.labshare.cn/cb-dock/php/</ext-link>) [<xref ref-type="bibr" rid="CR40">40</xref>]. The SDF structures of Cyclocreatine and Vorinostat were retrieved from the PubChem database, while PDB structures for PIAS1, PIAS2, PIAS3, and PIAS4 proteins were generated using the SwissModel tool. The docking process involved several key steps: [<xref ref-type="bibr" rid="CR1">1</xref>] Ligand Pre-processing: Both Cyclocreatine and Vorinostat were prepared by standardizing their structures for docking [<xref ref-type="bibr" rid="CR2">2</xref>]. Protein Preparation: The target proteins (PIAS1, PIAS2, PIAS3, and PIAS4) were processed by removing excess ligands and crystal water molecules from the PDB files, followed by the addition of hydrogen atoms [<xref ref-type="bibr" rid="CR3">3</xref>]. Molecular Docking: Docking simulations were performed using CB-DOCK to calculate the binding energies between the drugs and PIAS family proteins across multiple conformations [<xref ref-type="bibr" rid="CR3">3</xref>]. Conformation Selection: The conformation with the highest hydrogen bond energy was selected as the most favorable binding mode for drug-protein interaction. Finally, the molecular interactions and binding modes were visualized using PyMOL software (version 2.5.2) for a comprehensive understanding of the drug binding mechanisms.</p><p id="Par36">Following docking, MD simulations were conducted using the iMODS web server (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://imods.iqfr.csic.es/">http://imods.iqfr.csic.es/</ext-link>) to evaluate the flexibility and stability of the PIAS1, PIAS2, PIAS3, and PIAS4 proteins in the presence of Cyclocreatine. Deformability plots were generated to analyze the flexibility of protein residues, while B-factor calculations compared residue mobility between drug-bound (NMA) and unbound (PDB) states. Eigenvalue computation assessed the stiffness of the protein-drug complexes, with lower eigenvalues indicating greater flexibility, and variance analysis evaluated the contribution of principal modes to protein motion, revealing conformational changes induced by Cyclocreatine binding.</p></sec><sec id="Sec20"><title>Statistics</title><p id="Par37">In this study, GO and KEGG pathway enrichment analyses were performed using the&#8221; Fisher&#8217;s Exact Test to compute the statistical significance of the differences.&#8221; For correlational analysis, both the &#8220;Wilcoxon rank-sum test and the Pearson correlation method were applied, depending on the data type and distribution.&#8221; &#8220;Student&#8217;s t-test&#8221; was used to compare the means between two groups. All statistical analyses were conducted using R software (version 3.6.3) to ensure accurate data processing and visualization.</p></sec></sec></sec><sec id="Sec21"><title>Results</title><sec id="Sec22"><title>RT-qPCR analyses</title><p id="Par38">To investigate expression differences within the PIAS gene family among HNSC cell lines, the mRNA levels of PIAS1, PIAS2, PIAS3, and PIAS4 were assessed using RT-qPCR both the HNSC and control cell line samples. As depicted in Fig. 1&#8201;A, the mRNA expression levels of PIAS1, PIAS2, PIAS3, and PIAS4 were markedly up-regulated in the HNSC cell line group compared to the normal group, demonstrating statistical significance (p-value&#8201;&lt;&#8201;0.05) (Fig. 1&#8201;A). To assess the precision of PIAS1, PIAS2, PIAS3, and PIAS4 genes as potential diagnostic biomarkers for HNSC patients, ROC curves based on RT-qPCR data were generated (Fig.&#160;1B). The area under the ROC curve (AUC) for each of PIAS1, PIAS2, PIAS3, and PIAS4 surpassed 0.85, indicative of a high diagnostic accuracy for all the genes (Fig.&#160;1B).</p><p id="Par39">
<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>RT-qPCR expression and ROC analysis of PIAS family genes HNSC cell line samples. <bold>A</bold> Depicts the expressions of PIAS family genes in HNSC and normal control cell lines samples. <bold>B</bold> Presents ROC curves for the PIAS family genes based on the RT-qPCR expression. Significance was determined at a p-value&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e643" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig1_HTML.jpg"/></fig>
</p></sec><sec id="Sec24"><title>Association of promoter methylation with PIAS gene family expression</title><p id="Par40">A crucial factor influencing gene expression is promoter methylation, a significant epigenetic process. Any alterations or abnormalities in promoter methylation can lead to genetic anomalies such as cancer. The relationship between promoter methylation and the overexpression of the PIAS gene family in HNSC and normal cell line sample groups was examined using bisulfite sequencing analysis. The results of this analysis unveiled a substantial (p-value&#8201;&lt;&#8201;0.05) negative correlation between promoter methylation and the up-regulation of PIAS1, PIAS2, PIAS3, and PIAS4 in HNSC cell line group (Fig. 2&#8201;A). Consequently, we postulated that the overexpression of PIAS1, PIAS2, PIAS3, and PIAS4 might be attributed to promoter hypomethylation. Moreover, the area under the ROC curve (AUC) for each of PIAS1, PIAS2, PIAS3, and PIAS4 methylation-based ROC curve surpassed 0.8, indicative of a high diagnostic accuracy for all the genes (Fig.&#160;2B).</p><p id="Par41">
<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Bisulfite sequencing based promoter methylation levels and ROC analysis of PIAS family genes using HNSC cell lines. <bold>A</bold> Depicts the promoter methylation levels of PIAS family genes. <bold>B</bold> Presents ROC curves for the PIAS family genes based on the promoter methylation levels. Significance was determined at a p-value&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e664" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig2_HTML.jpg"/></fig>
</p></sec><sec id="Sec27"><title>Validation of PIAS family gene expression</title><p id="Par42">Within the TCGA datasets, UALCAN and GEPIA2 were employed for the validation of mRNA expression analyses for PIAS family genes in both HNSC and normal tissue sample groups. The UALCAN server was utilized to assess the mRNA expression levels of PIAS1, PIAS2, PIAS3, and PIAS4 in normal and HNSC samples, as depicted in Fig.&#160;3B, encompassing 44 normal and 520 TCGA HNSC samples. Additionally, the GEPIA2 server was involved in the analysis, incorporating a total of 44 healthy and 519 HNSC samples, as illustrated in Fig.&#160;3B. Overall, the results of the mRNA expression validation analysis across TCGA datasets further confirmed the significant (p-value&#8201;&lt;&#8201;0.05) up-regulation of PIAS1, PIAS2, PIAS3, and PIAS4 in the HNSC sample group compared to the normal sample group. Utilizing IHC, validation of the protein expression levels of PIAS1, PIAS2, PIAS3, and PIAS4 was conducted using data from the HPA database. The results of the analysis indicated that PIAS1, PIAS2, PIAS3, and PIAS4 exhibited high IHC staining in HNSC tissue samples, in contrast to the low staining observed in normal tissue samples (Fig. 3&#8201;C).</p><p id="Par43">
<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>This figure presents the validation of PIAS family gene expression using The Cancer Genome Atlas (TCGA) datasets and the Human Protein Atlas (HPA). <bold>A</bold> Validates mRNA expression through the UALCAN TCGA dataset. <bold>B</bold> Validates mRNA expression via the GEPIA TCGA dataset. <bold>C</bold> Confirms protein expression through the HPA database. Significance was determined at a p-value&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e688" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig3_HTML.jpg"/></fig>
</p></sec><sec id="Sec30"><title>Promoter methylation validation of PIAS family genes</title><p id="Par44">The validation of promoter methylation levels for PIAS1, PIAS2, PIAS3, and PIAS4 in both TCGA HNSC and normal tissue sample groups was conducted using MEXPRESS. The analysis outcomes demonstrated a noteworthy (p-value&#8201;&lt;&#8201;0.05) negative correlation between gene expression levels of PIAS1, PIAS2, PIAS3, and PIAS4 and their respective promoter methylation levels in HNSC samples, as illustrated in Fig.&#160;4. These findings further validate a significant association, indicating that alterations in promoter methylation contribute to the observed gene expression variations in PIAS family genes across HNSC samples.</p><p id="Par45">
<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>This figure shows the promoter methylation levels of the PIAS family genes across TCGA HNSC patients using MEXPRESS database. Significance was determined at a p-value&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e702" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig4_HTML.jpg"/></fig>
</p></sec><sec id="Sec34"><title>Mutational analysis of PIAS family genes</title><p id="Par46">The cBioPortal server was utilized to examine mutations in the PIAS1, PIAS2, PIAS3, and PIAS4 genes within HNSC. The selected TCGA HNSC dataset encompassed a total of 508 TCGA HNSC samples (Fig.&#160;5). The results indicated that alterations in PIAS1, PIAS2, PIAS3, and PIAS4 genes were observed in only 11 HNSC samples (Fig.&#160;5). These alterations included 2 T&#8201;&gt;&#8201;G mutations, 2 T&#8201;&gt;&#8201;C mutations, 4&#160;C&#8201;&gt;&#8201;T mutations, 4&#160;C&#8201;&gt;&#8201;G mutations, and 4&#160;C&#8201;&gt;&#8201;A missense mutations (Fig.&#160;5). Overall, given the low frequencies of these observed mutations in PIAS1, PIAS2, PIAS3, and PIAS4 genes across HNSC samples, it suggests that there may not be a significant correlation between the overexpression of PIAS1, PIAS2, PIAS3, and PIAS4 and the presence of mutations in HNSC.</p><p id="Par47">
<fig id="Fig5" position="float" orientation="portrait"><label>Fig. 5</label><caption><p>Exploration of genetic mutations in PIAS family genes across TCGA HNSC samples via the cBioPortal database</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e716" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig5_HTML.jpg"/></fig>
</p></sec><sec id="Sec35"><title>Survival analysis and construction of hub gene-based prognostic model</title><p id="Par48">Initially, the Kaplan&#8211;Meier plotter was employed for survival analysis, revealing that heightened expressions of PIAS1, PIAS2, PIAS3, and PIAS4 were correlated with poorer OS among patients with HNSC (Fig. 6&#8201;A). Subsequently, to construct a prognostic model involving PIAS1, PIAS2, PIAS3, and PIAS4 genes, we utilized the E_MTAB_8588 dataset as the training set, while <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE65858">GSE65858</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE75538">GSE75538</ext-link>, and TCGA_HNSC were employed for validation. Employing a stepwise Cox regression model with parameters such as hazard ratio, c-index, and risk score, we established this predictive model. Evaluation using the c-index demonstrated the model&#8217;s robustness in predicting the prognosis of HNSC patients across all analyzed datasets (Fig.&#160;6B, C).</p><p id="Par49">
<fig id="Fig6" position="float" orientation="portrait"><label>Fig. 6</label><caption><p>Survival analysis and the construction of the prognostic model. <bold>A</bold> KM plotter-based OS analysis of the PIAS family genes in HNSC patients. <bold>B</bold> Univariate Cox regression analysis. <bold>C</bold> Risk scores. A p-value&#8201;&lt;&#8201;0.05 was considered significant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e740" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig6_HTML.jpg"/></fig>
</p></sec><sec id="Sec36"><title>Correlation of PIAS family genes with immune cells</title><p id="Par50">The TISCH2 database was utilized to investigate the correlation between PIAS family gene expressions and various immune cells at the single-cell level across HNSC samples in HNSC_139324 dataset. The matrix heat map exhibited that PIAS1 expression has significant (p-value&#8201;&lt;&#8201;0.05) association with plasma cells (Fig.&#160;7), PIAS2 expression has significant (p-value&#8201;&lt;&#8201;0.05) association with Treg, Tprolif, CD8TEX, Plasma and Mast cells (Fig.&#160;7), and PIAS3 and PIAS 4 expressions have significant (p-value&#8201;&lt;&#8201;0.05) association with Plasma cells (Fig.&#160;7). However, these results are limited by reliance on a single dataset and RNA-level data, which may not fully reflect immune heterogeneity or protein-level activity, warranting further experimental validation.</p><p id="Par51">
<fig id="Fig7" position="float" orientation="portrait"><label>Fig. 7</label><caption><p>Correlation between PIAS family gene expression and different immune cells via the TISCH2 database. Significance was determined at a p-value&#8201;&lt;&#8201;0.05</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e754" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig7_HTML.jpg"/></fig>
</p></sec><sec id="Sec39"><title>Gene enrichment analysis</title><p id="Par52">Gene enrichment analysis of PIAS family genes was performed using DAVID tool. GO analysis of PIAS1, PIAS2, PIAS3, and PIAS4 genes indicated that those genes were involved in the &#8220;PML body, nuclear speck, and nuclear body&#8221; etc., CC terms (Fig. 8&#8201;A), &#8220;SUMO ligase activity, SUMO transferase activity, Potassium channel regulator activity&#8221; etc., MF terms (Fig.&#160;8B), &#8220;Pos. reg. of keratinocyte apoptotic proc, Pos. reg. of protein SUMOylation, Reg. of protein SUMOylation, and protein SUMOylation&#8221; etc., BP terms (Fig. 8&#8201;C). KEGG analysis of PIAS1, PIAS2, PIAS3, and PIAS4 showed that these genes were dominantly involved in the &#8220;Ubiquitin mediate proteolysis, JAK-STAT signaling pathway, NF-kappa B signaling pathway, fluid sheer stress and atherosclerosis, and hepatitis C&#8221; etc., signaling pathways (Fig.&#160;8D).</p><p id="Par53">
<fig id="Fig8" position="float" orientation="portrait"><label>Fig. 8</label><caption><p>Gene enrichment analysis of PIAS family genes. <bold>A</bold> CC terms, (<bold>B</bold>) MF terms, (<bold>C</bold>) BP terms, and (<bold>D</bold>) KEGG pathways. A p-value&#8201;&lt;&#8201;0.05 was used to show significant results</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e781" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig8_HTML.jpg"/></fig>
</p></sec><sec id="Sec40"><title>PIAS family genes knockdown inhibited the proliferation and migration of HNSC cells</title><p id="Par54">We proceeded to elucidate the impact of PIAS family gene expression on tumor growth and biological behavior through in vitro experiments. siRNAs were employed to knock down PIAS1, PIAS2, PIAS3, and PIAS4 mRNAs. The RT-qPCR analysis revealed a significant decrease in mRNA expression of PIAS1 (approximately 71%), PIAS2 (78%), PIAS3 (87%), and PIAS4 (79%) in the transfected HNSC cells (si-FaDu) compared to control HNSC cells (Ctrl-FaDu) (Fig. <xref rid="Fig9" ref-type="fig">9</xref>&#8201;A and Supplementary data Table&#160;1). These findings were further validated via Western blot analysis (Fig.&#160;9B and Supplementary data Fig.&#160;1). The results from the CCK-8 and colony formation assays showed a significant reduction in cell proliferation by approximately 53% and in colony numbers by about 75% in the transfected HNSC (si-FaDu) cells compared to the control group (Fig.&#160;<xref rid="Fig9" ref-type="fig">9</xref>C-E and Supplementary data Table&#160;2, and 3). Additionally, wound healing assay revealed a substantially reduced capacity for migration and invasion in PIAS1, PIAS2, PIAS3, and PIAS4 knockdown HNSC cells (35%) compared to the control cells (10%, Fig. 9&#8201;F).</p><p id="Par55">
<fig id="Fig9" position="float" orientation="portrait"><label>Fig. 9</label><caption><p>Knockdown of PIAS family impairs the growth and metastatic potential of FaDu HNSC cells. <bold>A</bold>, <bold>B</bold> The transfection efficiency of si-PIAS1, si-PIAS2, si-PIAS3, and si-PIAS4 was checked with the help of RT-qPCR and Western blot analyses, (<bold>C</bold>) FaDu control and transfected cells were analyzed for proliferation, (<bold>E</bold>, <bold>F</bold>) Colony formation and wound healing. A p-value&#8201;&lt;&#8201;0.05 was considered significant</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e817" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig9_HTML.jpg"/></fig>
</p></sec><sec id="Sec41"><title>Drugs acquisition and molecular docking analysis</title><p id="Par56">Initially, the DrugBank database was employed to identify PIAS1, PIAS2, PIAS3, and PIAS4 proteins inhibitory drug. Results showed that Cyclocreatine and Vorinostat drugs are capable to inhibit these proteins. In the next step, molecular docking was performed in to confirm the inhibitory effects of the Cyclocreatine and Vorinostat drugs on the PIAS1, PIAS2, PIAS3, and PIAS4 proteins. Molecular docking outcomes showed that Cyclocreatine and Vorinostat drugs have excellent binding energies (vina-scores) greater than&#8722;&#8201;5 (Fig. 10&#8201;A, B). To evaluate the structural flexibility and dynamic behavior of PIAS1&#8211;4 proteins in complex with Cyclocreatine, molecular dynamics simulations were performed using the iMODS server (Fig. 10&#8201;C). The deformability plots revealed flexible regions primarily in the C-terminal domains, with PIAS1 and PIAS4 showing higher deformability peaks (Fig. 10&#8201;C). B-factor comparisons between NMA-predicted and PDB-derived values showed good agreement, validating the simulation outputs (Fig. 10&#8201;C). The eigenvalue analysis indicated that PIAS1-Cyclocreatine had the lowest first eigenvalue (6.65e-08), suggesting greater structural flexibility, whereas PIAS4 was the most rigid (5.79e-09) (Fig. 10&#8201;C). Variance plots showed that the majority of molecular motion was captured within the first few modes across all complexes. These results suggest that PIAS1 exhibits the greatest conformational adaptability upon Cyclocreatine binding, which may influence its functional interactions (Fig. 10&#8201;C).</p><p id="Par57">
<fig id="Fig10" position="float" orientation="portrait"><label>Fig. 10</label><caption><p>Inhibition of PIAS proteins using Cyclocreatine and Vorinostat drugs via molecular docking and molecular dynamics (MD) simulation. <bold>A</bold> Inhibition of PIAS1, PIAS2, PIAS3, and PIAS4 using Cyclocreatine. <bold>B</bold> Inhibition of PIAS1, PIAS2, PIAS3, and PIAS4 using Vorinostat. <bold>C</bold>&#160;MD simulation analysis of PIAS1&#8211;4 proteins complexed with Cyclocreatine using the iMODS server</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e841" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig10_HTML.jpg"/></fig>
</p></sec></sec><sec id="Sec42"><title>Discussion</title><p id="Par58">HNSC ranks as the sixth most prevalent global cancer [<xref ref-type="bibr" rid="CR41">41</xref>&#8211;<xref ref-type="bibr" rid="CR43">43</xref>]. Despite a 5-year survival rate of less than 60% of HNSC patients, improvements have been elusive for over two decades, primarily attributable to the absence of accurate detection biomarkers [<xref ref-type="bibr" rid="CR44">44</xref>&#8211;<xref ref-type="bibr" rid="CR46">46</xref>]. The comprehensive investigation into the PIAS gene family in HNSC has provided valuable insights into its potential as diagnostic biomarkers, therapeutic targets, and prognostic indicators. The multifaceted approach, including RT-qPCR, promoter methylation assessment, validation across multiple datasets, functional assays, and molecular docking collectively paints a detailed picture of the role of PIAS1, PIAS2, PIAS3, and PIAS4 in HNSC.</p><p id="Par59">This study unveiled a significant up-regulation of PIAS1, PIAS2, PIAS3, and PIAS4 in HNSC samples compared to normal tissues. This overexpression is consistent with the aberrant expression patterns observed in various cancers, suggesting a potential oncogenic role for the PIAS family in HNSC. For example, earlier studies have implicated their aberrant expression or altered activity in cancers such as breast, colorectal, and prostate cancer, impacting key cellular processes like proliferation, apoptosis, and immune response modulation [<xref ref-type="bibr" rid="CR47">47</xref>&#8211;<xref ref-type="bibr" rid="CR50">50</xref>]. The robust diagnostic potential of these genes was confirmed through ROC curve analysis, where high AUC values indicated their efficacy as diagnostic biomarkers. These outcomes emphasize the clinical relevance of PIAS1, PIAS2, PIAS3, and PIAS4 in distinguishing HNSC from normal tissues.</p><p id="Par60">The correlation between promoter methylation and gene expression provides crucial insights into the regulatory mechanisms of the PIAS family in HNSC. The negative correlation observed between promoter methylation and the up-regulation of PIAS1, PIAS2, PIAS3, and PIAS4 suggests that hypomethylation may contribute to their overexpression. This epigenetic dysregulation aligns with the well-established concept that altered DNA methylation patterns play a pivotal role in cancer initiation and progression [<xref ref-type="bibr" rid="CR51">51</xref>&#8211;<xref ref-type="bibr" rid="CR54">54</xref>]. Moreover, best to our knowledge, we are the first to report PIAS family gene hypomethylation in HNSC patients.</p><p id="Par61">The low frequency of mutations in PIAS genes in HNSC, as revealed by cBioPortal analysis, suggests that overexpression may not be primarily driven by genetic alterations. Furthermore, survival analysis demonstrated a correlation between elevated PIAS expression and poorer overall survival in HNSC patients. Consistent with our observations in HNSC, earlier research has signified the prognostic value of elevated PIAS expression in determining overall survival outcomes in other malignancies, including breast and colorectal cancers [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. The establishment of a prognostic model using diverse TCGA datasets not only reinforces the role of PIAS genes as robust prognostic indicators in HNSC but also aligns with a broader body of evidence recognizing their prognostic relevance across different cancer types. In sum, this collective evidence strengthens the notion that PIAS family genes may serve as universal prognostic markers in cancer.</p><p id="Par62">Exploring the correlation between PIAS family gene expressions and immune cells at the single-cell level using the TISCH2 database provides additional layers of information. Significant associations with specific immune cells suggest a potential role of PIAS genes in modulating the tumor microenvironment and immune response in HNSC. The observed associations could influence the development of targeted immunotherapies. Moreover, functional assays, including CCK-8, colony formation, and wound healing, emphasized the biological significance of PIAS family genes in HNSC. Knockdown of PIAS1, PIAS2, PIAS3, and PIAS4 resulted in reduced cell viability, colony formation, migration, and invasion, indicating their pivotal role in promoting tumor growth and aggressiveness. GO and KEGG analyses revealed the involvement of PIAS genes in various cellular components, molecular functions, biological processes, and signaling pathways. The roles of explored pathways involving PIAS genes, including &#8220;Ubiquitin mediate proteolysis, JAK-STAT signaling pathway, NF-kappa B signaling pathway, fluid sheer stress and atherosclerosis, and hepatitis C&#8221; etc., signaling pathways are already well studied in cancer development and progression [<xref ref-type="bibr" rid="CR57">57</xref>&#8211;<xref ref-type="bibr" rid="CR61">61</xref>]. Among the explored pathways, the JAK-STAT and NF-&#954;B pathways are particularly relevant to HNSC pathogenesis. PIAS proteins regulate transcription factors through SUMOylation, a post-translational modification that alters their activity, localization, or stability [<xref ref-type="bibr" rid="CR62">62</xref>]. In the context of HNSC, SUMOylation of STAT3 by PIAS family members can inhibit its transcriptional activity [<xref ref-type="bibr" rid="CR63">63</xref>]. Given that constitutive activation of STAT3 is a well-established driver of tumor growth, immune evasion, and resistance to apoptosis in HNSC [<xref ref-type="bibr" rid="CR64">64</xref>], PIAS-mediated repression of STAT3 may function as a tumor-suppressive mechanism [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR65">65</xref>]. Furthermore, PIAS proteins also modulate p53, a critical tumor suppressor frequently dysregulated in HNSC, by influencing its SUMOylation status, thereby impacting DNA damage responses and apoptosis [<xref ref-type="bibr" rid="CR66">66</xref>]. The up-regulation of PIAS family members, especially PIAS1 and PIAS4, is a critical mechanistic driver of HNSC pathogenesis because it significantly alters the Small Ubiquitin-like Modifier (SUMO) conjugation system (Fig. <xref rid="Fig11" ref-type="fig">11</xref>). This leads to aberrant SUMOylation of key cellular regulators. Specifically, the enhanced E3 SUMO ligase activity of PIAS proteins causes the SUMOylation and functional inactivation of the tumor suppressor protein p53, which impairs its ability to initiate crucial tumor-suppressive functions like cell cycle arrest and apoptosis (Fig. <xref rid="Fig11" ref-type="fig">11</xref>). Additionally, PIAS4-mediated SUMOylation of DNA repair proteins, such as BRCA1, can disrupt the DNA Damage Response (DDR) pathway (Fig. <xref rid="Fig11" ref-type="fig">11</xref>). This disruption contributes directly to genomic instability and the accumulation of oncogenic mutations, both of which are central hallmarks of HNSC initiation and progression (Fig. <xref rid="Fig11" ref-type="fig">11</xref>). This complex dysregulation suggests that PIAS proteins are promising therapeutic targets for neutralizing SUMO-driven oncogenic signaling in HNSC (Fig. <xref rid="Fig11" ref-type="fig">11</xref>). Beyond JAK-STAT and NF-&#954;B, PIAS proteins interact with other oncogenic pathways relevant to HNSC, such as the epidermal growth factor receptor (EGFR) signaling axis [<xref ref-type="bibr" rid="CR67">67</xref>]. EGFR overexpression and activation are common in HNSC and promote proliferation and survival. PIAS-mediated SUMOylation can affect downstream transcription factors and signaling components linked to EGFR, indirectly modulating oncogenic signaling cascades [<xref ref-type="bibr" rid="CR68">68</xref>]. By controlling the SUMOylation of key transcription factors and signaling molecules, PIAS proteins play a nuanced role in balancing oncogenic and tumor-suppressive signals within HNSC cells. This regulatory complexity emphasizes the potential of targeting PIAS-mediated SUMOylation as a therapeutic strategy, warranting further investigation into its mechanistic contributions to HNSC pathogenesis and treatment resistance.</p><p id="Par63">
<fig id="Fig11" position="float" orientation="portrait"><label>Fig. 11</label><caption><p>Mechanistic Pathway of PIAS-Mediated Oncogenesis in HNSC</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="d33e943" position="float" orientation="portrait" xlink:href="12672_2025_4100_Fig11_HTML.jpg"/></fig>
</p><p id="Par64">Via the DrugBank database, we have identified two important drugs, including Cyclocreatine and Vorinostat for inhibiting PIAS1, PIAS2, PIAS3, and PIAS4. Cyclocreatine targets energy metabolism, inhibiting cancer cell proliferation, while Vorinostat is a histone deacetylase inhibitor [<xref ref-type="bibr" rid="CR69">69</xref>, <xref ref-type="bibr" rid="CR70">70</xref>]. Molecular docking analysis indicated potential binding affinities between these compounds and PIAS family proteins, suggesting a plausible mechanism for inhibitory activity. However, these results are based solely on in silico modeling and have not yet been validated experimentally. Therefore, these findings provide a foundation for further molecular experimental research to investigate the therapeutic potential of Cyclocreatine and Vorinostat targeting PIAS proteins.</p><p id="Par65">This study offers valuable insights into the role of the PIAS gene family in HNSC by employing a variety of molecular techniques to validate the gene expression and its potential as diagnostic markers. The use of RT-qPCR provided strong evidence of significant up-regulation of PIAS1, PIAS2, PIAS3, and PIAS4 in HNSC cell lines, reinforcing their potential as biomarkers for diagnosis. The ROC curve analysis further supported this, demonstrating high diagnostic accuracy with AUC values exceeding 0.85. Additionally, the integration of promoter methylation analysis revealed the important role of epigenetic modifications in regulating PIAS gene expression, potentially providing therapeutic avenues. The mutational analysis and survival analysis highlighted the clinical relevance of these genes in predicting patient prognosis and their association with immune cells and tumor pathways emphasizing their dual potential as both biomarkers and therapeutic targets. The study also advanced the field by employing molecular docking to identify Cyclocreatine and Vorinostat as potential inhibitors of PIAS family proteins, further offering a foundation for targeted drug development.</p><p id="Par66">Despite the significant findings, this study has several limitations. First, the mutational analysis showed a low frequency of alterations in the PIAS family genes, which raises questions about the generalizability of their involvement in HNSC pathogenesis. The limited number of mutations observed suggests that gene expression alterations may not be primarily driven by mutations in these genes, and other regulatory mechanisms might be at play. Secondly, while in silico analyses and in vitro experiments provided robust evidence for the up-regulation and diagnostic potential of the PIAS genes, these findings need to be validated in clinical tissue samples and patient cohorts to confirm their relevance in clinical settings. Additionally, the molecular docking analysis using Cyclocreatine and Vorinostat was based on computational predictions, and further in vivo studies are required to confirm the efficacy and safety of these drugs in HNSC treatment. Finally, while the study highlights the immune modulation by PIAS family genes, more detailed immune cell profiling and in vivo models are needed to fully elucidate their role in immune evasion and tumor progression in HNSC.</p></sec><sec id="Sec43"><title>Conclusion</title><p id="Par67">This study provides a comprehensive analysis of the PIAS family genes (PIAS1, PIAS2, PIAS3, and PIAS4) in HNSC, highlighting their significant potential as diagnostic biomarkers and therapeutic targets. Through a combination of molecular techniques, including RT-qPCR, Western blot, and immunohistochemistry (IHC), we demonstrated that the PIAS genes are significantly up-regulated in HNSC cell lines compared to normal tissues. The ROC curve analysis further confirmed their diagnostic potential with high accuracy, supporting the idea that these genes could be employed for early detection and prognosis of HNSC. The study also explored the epigenetic regulation of PIAS gene expression by investigating promoter methylation. The negative correlation between promoter methylation and gene expression suggests that hypomethylation may be a key mechanism contributing to the overexpression of these genes in cancerous tissues. Additionally, the mutational analysis conducted using the cBioPortal database revealed low frequencies of mutations in the PIAS genes, suggesting that gene expression alterations may not be primarily driven by mutations. However, the presence of mutations in a small subset of samples highlights the potential for further exploration of these genes in genetic studies. The survival analysis indicated that the expression of PIAS genes correlates with poor prognosis in HNSC patients, reinforcing their role in tumor progression and making them viable candidates for prognostic markers. The study also examined the correlation between PIAS gene expression and immune cells using the TISCH2 database. The significant associations between PIAS gene expression and various immune cell populations suggest a role for these genes in immune modulation, which may have implications for tumor immunology and the development of immunotherapies. Furthermore, the gene enrichment analysis provided evidence that these genes are involved in crucial biological processes such as protein SUMOylation and signaling pathways like JAK-STAT and NF-kappa B, which are critical in cancer progression and immune responses. The application of molecular docking techniques to identify potential inhibitors of the PIAS family proteins, such as Cyclocreatine and Vorinostat, opens the door to drug development targeting these proteins. However, while the computational predictions are promising, further in vivo validation and clinical trials are necessary to assess the efficacy and safety of these potential therapies. In sum, this study underscores the significant role of PIAS family genes in HNSC and their potential as both diagnostic biomarkers and therapeutic targets. The findings pave the way for future research focused on clinical validation and the development of targeted therapies aimed at modulating PIAS gene expression and function. While further studies are needed to fully elucidate their molecular mechanisms, the PIAS family genes represent a promising area for future exploration in head and neck cancer research.</p></sec><sec id="Sec44" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12672_2025_4100_MOESM1_ESM.pdf" position="float" orientation="portrait"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors extend their appreciation to the ongoing Research Funding Program (ORF-2025-470) King Saud University, Riyadh, Saud Arabia.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Mumtaz Hussain conceptualized the study, designed the methodology, and wrote the manuscript. Mehreen Ishfaq conducted data analysis and contributed to the interpretation of results. Syeda Amber Hameed assisted with the literature review and helped in drafting the manuscript. Afshan Syed Abbas performed laboratory experiments and contributed to data collection. Mujeeb ur Rehman Bhanbhro managed the data, contributed to statistical analysis, and assisted with manuscript revisions. Qurat ul Ain and Muhammad Mazhar Ayaz coordinated the research work and contributed to the analysis and interpretation of results. Mostafa A. Abdel-Maksoud provided expert input on the methodology and contributed to the final review of the manuscript. Abdulaziz Alamri assisted with the experimental design and data validation. Saeedah Almutairi contributed to data interpretation and manuscript revision. Taghreed N. Almanaa assisted with the interpretation of experimental data and contributed to manuscript preparation. Yasir Hameed supervised the study, provided overall guidance, and critically reviewed the manuscript. All authors reviewed and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>The authors extend their appreciation to the ongoing Research Funding Program (ORF-2025-470) King Saud University,Riyadh, Saud Arabia.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>All data utilized in this study were obtained from publicly accessible repositories. The TCGA HNSC datasets were accessed via the UALCAN ([http://ualcan.path.uab.edu](http:/ualcan.path.uab.edu)), GEPIA2 ([http://gepia2.cancer-pku.cn](http:/gepia2.cancer-pku.cn)), and MEXPRESS ([https://mexpress.be](https:/mexpress.be)) portals. Mutational and genomic alteration data were retrieved from cBioPortal ([https://www.cbioportal.org](https:/www.cbioportal.org)). Single-cell RNA sequencing data were obtained from TISCH2 ([http://tisch.comp-genomics.org](http:/tisch.comp-genomics.org)), and functional enrichment analyses were conducted using the DAVID database ([https://david.ncifcrf.gov](https:/david.ncifcrf.gov)). Molecular docking was performed using CB-DOCK ([http://clab.labshare.cn/cb-dock/php/](http:/clab.labshare.cn/cb-dock/php)), while molecular dynamics simulations were conducted via iMODS ([http://imods.iqfr.csic.es](http:/imods.iqfr.csic.es)). All datasets are publicly available, and accession numbers or dataset identifiers (TCGA-HNSC, E-MTAB-8588, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE65858">GSE65858</ext-link>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE75538">GSE75538</ext-link>) have been cited in the relevant sections. No new datasets were generated or deposited as part of this study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par68">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par69">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par70">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parashar</surname><given-names>P</given-names></name><name name-style="western"><surname>Hungyo</surname><given-names>H</given-names></name><name name-style="western"><surname>Jain</surname><given-names>A</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>S</given-names></name><name name-style="western"><surname>Tandon</surname><given-names>V</given-names></name></person-group><article-title>Unraveling molecular mechanisms of head and neck cancer</article-title><source>Crit Rev Oncol Hematol</source><year>2022</year><pub-id pub-id-type="doi">10.1016/j.critrevonc.2022.103778</pub-id><pub-id pub-id-type="pmid">35932993</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Parashar P, Hungyo H, Jain A, Ahmad S, Tandon V. Unraveling molecular mechanisms of head and neck cancer. Crit Rev Oncol Hematol. 2022. 10.1016/j.critrevonc.2022.103778.<pub-id pub-id-type="pmid">35932993</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.critrevonc.2022.103778</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Khera N, Rajkumar AS, Abdulkader M Alkurdi K, Liu Z, Ma H, Waseem A, Teh MT. Identification of multidrug chemoresistant genes in head and neck squamous cell carcinoma cells. Mol Cancer. 2023;22(1):146.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-023-01846-3</pub-id><pub-id pub-id-type="pmcid">PMC10476423</pub-id><pub-id pub-id-type="pmid">37667354</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sial</surname><given-names>N</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M</given-names></name><name name-style="western"><surname>Hussain</surname><given-names>MS</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Hameed</surname><given-names>Y</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M</given-names></name><etal/></person-group><article-title>CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes</article-title><source>Sci Rep</source><year>2021</year><volume>11</volume><issue>1</issue><fpage>19873</fpage><pub-id pub-id-type="doi">10.1038/s41598-021-99321-w</pub-id><pub-id pub-id-type="pmid">34615943</pub-id><pub-id pub-id-type="pmcid">PMC8494806</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Sial N, Ahmad M, Hussain MS, Iqbal MJ, Hameed Y, Khan M, et al. CTHRC1 expression is a novel shared diagnostic and prognostic biomarker of survival in six different human cancer subtypes. Sci Rep. 2021;11(1):19873.<pub-id pub-id-type="pmid">34615943</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-99321-w</pub-id><pub-id pub-id-type="pmcid">PMC8494806</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>A-J</given-names></name><name name-style="western"><surname>You</surname><given-names>G-R</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C-J</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y-C</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S-J</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y-F</given-names></name><etal/></person-group><article-title>Systemic investigation identifying salivary miR-196b as a promising biomarker for early detection of head-neck cancer and oral precancer lesions</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><issue>8</issue><fpage>1411</fpage><pub-id pub-id-type="doi">10.3390/diagnostics11081411</pub-id><pub-id pub-id-type="pmid">34441345</pub-id><pub-id pub-id-type="pmcid">PMC8392418</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Cheng A-J, You G-R, Lee C-J, Lu Y-C, Tang S-J, Huang Y-F, et al. Systemic investigation identifying salivary miR-196b as a promising biomarker for early detection of head-neck cancer and oral precancer lesions. Diagnostics. 2021;11(8):1411.<pub-id pub-id-type="pmid">34441345</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics11081411</pub-id><pub-id pub-id-type="pmcid">PMC8392418</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Qu</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Feng</surname><given-names>G</given-names></name><name name-style="western"><surname>Chen</surname><given-names>C</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>S</given-names></name><etal/></person-group><article-title>RPA 3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma</article-title><source>J Cell Mol Med</source><year>2017</year><volume>21</volume><issue>11</issue><fpage>2872</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1111/jcmm.13200</pub-id><pub-id pub-id-type="pmid">28557284</pub-id><pub-id pub-id-type="pmcid">PMC5661258</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Qu C, Zhao Y, Feng G, Chen C, Tao Y, Zhou S, et al. RPA 3 is a potential marker of prognosis and radioresistance for nasopharyngeal carcinoma. J Cell Mol Med. 2017;21(11):2872&#8211;83.<pub-id pub-id-type="pmid">28557284</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcmm.13200</pub-id><pub-id pub-id-type="pmcid">PMC5661258</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rayan</surname><given-names>A</given-names></name><name name-style="western"><surname>Shehata</surname><given-names>S</given-names></name><name name-style="western"><surname>Aboshanif</surname><given-names>MM</given-names></name><name name-style="western"><surname>Aleem</surname><given-names>DA</given-names></name><name name-style="western"><surname>El-Naggar</surname><given-names>MS</given-names></name></person-group><article-title>The addition of docetaxel to platinum based concurrent chemoradiation improves the response and survival in patients with locally advanced squamous cell carcinoma of head and neck; phase II study</article-title><source>Eurasian J Med Oncol</source><year>2024</year><volume>8</volume><issue>1</issue><fpage>49</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.14744/ejmo.2024.21999</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Rayan A, Shehata S, Aboshanif MM, Aleem DA, El-Naggar MS. The addition of docetaxel to platinum based concurrent chemoradiation improves the response and survival in patients with locally advanced squamous cell carcinoma of head and neck; phase II study. Eurasian J Med Oncol. 2024;8(1):49&#8211;58.</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Debes</surname><given-names>JD</given-names></name><name name-style="western"><surname>Chan</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Balderramo</surname><given-names>D</given-names></name><name name-style="western"><surname>Kikuchi</surname><given-names>L</given-names></name><name name-style="western"><surname>Gonzalez Ballerga</surname><given-names>E</given-names></name><name name-style="western"><surname>Prieto</surname><given-names>JE</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma in South America: evaluation of risk factors, demographics and therapy</article-title><source>Liver Int</source><year>2018</year><volume>38</volume><issue>1</issue><fpage>136</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1111/liv.13502</pub-id><pub-id pub-id-type="pmid">28640517</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Debes JD, Chan AJ, Balderramo D, Kikuchi L, Gonzalez Ballerga E, Prieto JE, et al. Hepatocellular carcinoma in South America: evaluation of risk factors, demographics and therapy. Liver Int. 2018;38(1):136&#8211;43.<pub-id pub-id-type="pmid">28640517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/liv.13502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>H</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>C</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma</article-title><source>Comput Biol Med</source><year>2024</year><volume>171</volume><fpage>108198</fpage><pub-id pub-id-type="doi">10.1016/j.compbiomed.2024.108198</pub-id><pub-id pub-id-type="pmid">38417385</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gong H, Liu Z, Yuan C, Luo Y, Chen Y, Zhang J, et al. Identification of cuproptosis-related lncRNAs with the significance in prognosis and immunotherapy of oral squamous cell carcinoma. Comput Biol Med. 2024;171:108198.<pub-id pub-id-type="pmid">38417385</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compbiomed.2024.108198</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>M</given-names></name><name name-style="western"><surname>Rosenbaum</surname><given-names>E</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>AL</given-names></name><name name-style="western"><surname>Koch</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>W</given-names></name><name name-style="western"><surname>Sidransky</surname><given-names>D</given-names></name><etal/></person-group><article-title>Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer</article-title><source>Int J Cancer</source><year>2005</year><volume>117</volume><issue>4</issue><fpage>605</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1002/ijc.21216</pub-id><pub-id pub-id-type="pmid">15929076</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Zhao M, Rosenbaum E, Carvalho AL, Koch W, Jiang W, Sidransky D, et al. Feasibility of quantitative PCR-based saliva rinse screening of HPV for head and neck cancer. Int J Cancer. 2005;117(4):605&#8211;10.<pub-id pub-id-type="pmid">15929076</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.21216</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usman</surname><given-names>M</given-names></name><name name-style="western"><surname>Okla</surname><given-names>MK</given-names></name><name name-style="western"><surname>Asif</surname><given-names>HM</given-names></name><name name-style="western"><surname>AbdElgayed</surname><given-names>G</given-names></name><name name-style="western"><surname>Muccee</surname><given-names>F</given-names></name><name name-style="western"><surname>Ghazanfar</surname><given-names>S</given-names></name><etal/></person-group><article-title>A pan-cancer analysis of GINS complex subunit 4 to identify its potential role as a biomarker in multiple human cancers</article-title><source>Am J Cancer Res</source><year>2022</year><volume>12</volume><issue>3</issue><fpage>986</fpage><pub-id pub-id-type="pmid">35411239</pub-id><pub-id pub-id-type="pmcid">PMC8984884</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Usman M, Okla MK, Asif HM, AbdElgayed G, Muccee F, Ghazanfar S, et al. A pan-cancer analysis of GINS complex subunit 4 to identify its potential role as a biomarker in multiple human cancers. Am J Cancer Res. 2022;12(3):986.<pub-id pub-id-type="pmid">35411239</pub-id><pub-id pub-id-type="pmcid">PMC8984884</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>J</given-names></name></person-group><article-title>Inferring latent microRNA-disease associations on a gene-mediated tripartite heterogeneous multiplexing network</article-title><source>IEEE ACM Trans Comput Biol Bioinf</source><year>2022</year><volume>19</volume><issue>6</issue><fpage>3190</fpage><lpage>201</lpage><pub-id pub-id-type="doi">10.1109/TCBB.2022.3143770</pub-id><pub-id pub-id-type="pmid">35041612</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Li W, Wang S, Xu J, Xiang J. Inferring latent microRNA-disease associations on a gene-mediated tripartite heterogeneous multiplexing network. IEEE ACM Trans Comput Biol Bioinf. 2022;19(6):3190&#8211;201.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TCBB.2022.3143770</pub-id><pub-id pub-id-type="pmid">35041612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Talor</surname><given-names>E</given-names></name><name name-style="western"><surname>T&#237;m&#225;r</surname><given-names>J</given-names></name><name name-style="western"><surname>Lavin</surname><given-names>P</given-names></name><name name-style="western"><surname>Cipriano</surname><given-names>J</given-names></name><name name-style="western"><surname>Markovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Lad&#225;nyi</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma&#8211;the IT-MATTERS study</article-title><source>Pathol Oncol Res</source><year>2025</year><volume>31</volume><fpage>1612084</fpage><pub-id pub-id-type="doi">10.3389/pore.2025.1612084</pub-id><pub-id pub-id-type="pmid">40191245</pub-id><pub-id pub-id-type="pmcid">PMC11968324</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Talor E, T&#237;m&#225;r J, Lavin P, Cipriano J, Markovic D, Lad&#225;nyi A, et al. Neoadjuvant leukocyte interleukin injection immunotherapy improves overall survival in low-risk locally advanced head and neck squamous cell carcinoma&#8211;the IT-MATTERS study. Pathol Oncol Res. 2025;31:1612084.<pub-id pub-id-type="pmid">40191245</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/pore.2025.1612084</pub-id><pub-id pub-id-type="pmcid">PMC11968324</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seif</surname><given-names>F</given-names></name><name name-style="western"><surname>Khoshmirsafa</surname><given-names>M</given-names></name><name name-style="western"><surname>Aazami</surname><given-names>H</given-names></name><name name-style="western"><surname>Mohsenzadegan</surname><given-names>M</given-names></name><name name-style="western"><surname>Sedighi</surname><given-names>G</given-names></name><name name-style="western"><surname>Bahar</surname><given-names>M</given-names></name></person-group><article-title>The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells</article-title><source>Cell Commun Signal</source><year>2017</year><volume>15</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1186/s12964-017-0177-y</pub-id><pub-id pub-id-type="pmid">28637459</pub-id><pub-id pub-id-type="pmcid">PMC5480189</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017;15:1&#8211;13.<pub-id pub-id-type="pmid">28637459</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12964-017-0177-y</pub-id><pub-id pub-id-type="pmcid">PMC5480189</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>X</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Fu</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name></person-group><article-title>The JAK/STAT signaling pathway: from bench to clinic</article-title><source>Signal Transduct Target Ther</source><year>2021</year><volume>6</volume><issue>1</issue><fpage>402</fpage><pub-id pub-id-type="doi">10.1038/s41392-021-00791-1</pub-id><pub-id pub-id-type="pmid">34824210</pub-id><pub-id pub-id-type="pmcid">PMC8617206</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6(1):402.<pub-id pub-id-type="pmid">34824210</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-021-00791-1</pub-id><pub-id pub-id-type="pmcid">PMC8617206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loh</surname><given-names>C-Y</given-names></name><name name-style="western"><surname>Arya</surname><given-names>A</given-names></name><name name-style="western"><surname>Naema</surname><given-names>AF</given-names></name><name name-style="western"><surname>Wong</surname><given-names>WF</given-names></name><name name-style="western"><surname>Sethi</surname><given-names>G</given-names></name><name name-style="western"><surname>Looi</surname><given-names>CY</given-names></name></person-group><article-title>Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: functions and therapeutic implication</article-title><source>Front Oncol</source><year>2019</year><volume>9</volume><fpage>48</fpage><pub-id pub-id-type="doi">10.3389/fonc.2019.00048</pub-id><pub-id pub-id-type="pmid">30847297</pub-id><pub-id pub-id-type="pmcid">PMC6393348</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Loh C-Y, Arya A, Naema AF, Wong WF, Sethi G, Looi CY. Signal transducer and activator of transcription (STATs) proteins in cancer and inflammation: functions and therapeutic implication. Front Oncol. 2019;9:48.<pub-id pub-id-type="pmid">30847297</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fonc.2019.00048</pub-id><pub-id pub-id-type="pmcid">PMC6393348</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>McManus</surname><given-names>FP</given-names></name><name name-style="western"><surname>Plutoni</surname><given-names>C</given-names></name><name name-style="western"><surname>Pascariu</surname><given-names>CM</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>T</given-names></name><name name-style="western"><surname>Alberici Delsin</surname><given-names>LE</given-names></name><etal/></person-group><article-title>Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>834</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-14581-w</pub-id><pub-id pub-id-type="pmid">32047143</pub-id><pub-id pub-id-type="pmcid">PMC7012886</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Li C, McManus FP, Plutoni C, Pascariu CM, Nelson T, Alberici Delsin LE, et al. Quantitative SUMO proteomics identifies PIAS1 substrates involved in cell migration and motility. Nat Commun. 2020;11(1):834.<pub-id pub-id-type="pmid">32047143</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-020-14581-w</pub-id><pub-id pub-id-type="pmcid">PMC7012886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>S</given-names></name><name name-style="western"><surname>Li</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qiao</surname><given-names>X</given-names></name><name name-style="western"><surname>Jin</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>R</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>A protein inhibitor of activated STAT (CgPIAS) negatively regulates the expression of ISGs by inhibiting STAT activation in oyster Crassostrea gigas</article-title><source>Fish Shellfish Immunol</source><year>2022</year><volume>131</volume><fpage>1214</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.fsi.2022.11.020</pub-id><pub-id pub-id-type="pmid">36410649</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wang S, Li Y, Qiao X, Jin Y, Liu R, Wang L, et al. A protein inhibitor of activated STAT (CgPIAS) negatively regulates the expression of ISGs by inhibiting STAT activation in oyster Crassostrea gigas. Fish Shellfish Immunol. 2022;131:1214&#8211;23.<pub-id pub-id-type="pmid">36410649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.fsi.2022.11.020</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Du</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>S</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name></person-group><article-title>The role of SUMO E3 ligases in signaling pathway of cancer cells</article-title><source>Int J Mol Sci</source><year>2022</year><volume>23</volume><issue>7</issue><fpage>3639</fpage><pub-id pub-id-type="doi">10.3390/ijms23073639</pub-id><pub-id pub-id-type="pmid">35408996</pub-id><pub-id pub-id-type="pmcid">PMC8998487</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Shi X, Du Y, Li S, Wu H. The role of SUMO E3 ligases in signaling pathway of cancer cells. Int J Mol Sci. 2022;23(7):3639.<pub-id pub-id-type="pmid">35408996</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms23073639</pub-id><pub-id pub-id-type="pmcid">PMC8998487</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>W</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Fan</surname><given-names>K</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name></person-group><article-title>PIAS3 promotes ferroptosis by regulating TXNIP via TGF-&#946; signaling pathway in hepatocellular carcinoma</article-title><source>Pharmacol Res</source><year>2023</year><volume>196</volume><fpage>106915</fpage><pub-id pub-id-type="doi">10.1016/j.phrs.2023.106915</pub-id><pub-id pub-id-type="pmid">37689128</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Bao W, Wang J, Fan K, Gao Y, Chen J. PIAS3 promotes ferroptosis by regulating TXNIP via TGF-&#946; signaling pathway in hepatocellular carcinoma. Pharmacol Res. 2023;196:106915.<pub-id pub-id-type="pmid">37689128</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2023.106915</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dubey</surname><given-names>AR</given-names></name><name name-style="western"><surname>Patwa</surname><given-names>SM</given-names></name><name name-style="western"><surname>Kinger</surname><given-names>S</given-names></name><name name-style="western"><surname>Jagtap</surname><given-names>YA</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><etal/></person-group><article-title>Improper proteostasis: can it serve as biomarkers for neurodegenerative diseases?</article-title><source>Mol Neurobiol</source><year>2022</year><volume>59</volume><issue>6</issue><fpage>3382</fpage><lpage>401</lpage><pub-id pub-id-type="doi">10.1007/s12035-022-02775-w</pub-id><pub-id pub-id-type="pmid">35305242</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Dubey AR, Patwa SM, Kinger S, Jagtap YA, Kumar P, Singh S, et al. Improper proteostasis: can it serve as biomarkers for neurodegenerative diseases? Mol Neurobiol. 2022;59(6):3382&#8211;401.<pub-id pub-id-type="pmid">35305242</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12035-022-02775-w</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McAllister</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Underwood</surname><given-names>MA</given-names></name><name name-style="western"><surname>Leung</surname><given-names>HY</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>J</given-names></name></person-group><article-title>A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer</article-title><source>Transl Res</source><year>2019</year><volume>206</volume><fpage>91</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.trsl.2018.11.004</pub-id><pub-id pub-id-type="pmid">30528321</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">McAllister MJ, Underwood MA, Leung HY, Edwards J. A review on the interactions between the tumor microenvironment and androgen receptor signaling in prostate cancer. Transl Res. 2019;206:91&#8211;106.<pub-id pub-id-type="pmid">30528321</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trsl.2018.11.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>SC</given-names></name><name name-style="western"><surname>Ding</surname><given-names>JL</given-names></name></person-group><article-title>Ubiquitination and SUMOylation in the chronic inflammatory tumor microenvironment</article-title><source>Biochimica et Biophysica Acta (BBA)-Reviews on Cancer</source><year>2018</year><volume>1870</volume><issue>2</issue><fpage>165</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.bbcan.2018.08.002</pub-id><pub-id pub-id-type="pmid">30318471</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Chang SC, Ding JL. Ubiquitination and SUMOylation in the chronic inflammatory tumor microenvironment. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2018;1870(2):165&#8211;75.<pub-id pub-id-type="pmid">30318471</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bbcan.2018.08.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hargadon</surname><given-names>KM</given-names></name></person-group><article-title>Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer</article-title><source>Cell Mol Life Sci</source><year>2023</year><volume>80</volume><issue>2</issue><fpage>40</fpage><pub-id pub-id-type="doi">10.1007/s00018-023-04689-9</pub-id><pub-id pub-id-type="pmid">36629955</pub-id><pub-id pub-id-type="pmcid">PMC11072992</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Hargadon KM. Genetic dysregulation of immunologic and oncogenic signaling pathways associated with tumor-intrinsic immune resistance: a molecular basis for combination targeted therapy-immunotherapy for cancer. Cell Mol Life Sci. 2023;80(2):40.<pub-id pub-id-type="pmid">36629955</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00018-023-04689-9</pub-id><pub-id pub-id-type="pmcid">PMC11072992</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>B</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liao</surname><given-names>B</given-names></name><name name-style="western"><surname>Lang</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><etal/></person-group><article-title>Gene coexpression network and module analysis across 52 human tissues</article-title><source>Biomed Res Int</source><year>2020</year><volume>2020</volume><issue>1</issue><fpage>6782046</fpage><pub-id pub-id-type="doi">10.1155/2020/6782046</pub-id><pub-id pub-id-type="pmid">32462012</pub-id><pub-id pub-id-type="pmcid">PMC7232734</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">He B, Xu J, Tian Y, Liao B, Lang J, Lin H, et al. Gene coexpression network and module analysis across 52 human tissues. Biomed Res Int. 2020;2020(1):6782046.<pub-id pub-id-type="pmid">32462012</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2020/6782046</pub-id><pub-id pub-id-type="pmcid">PMC7232734</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>C</given-names></name><name name-style="western"><surname>Kuang</surname><given-names>M</given-names></name><name name-style="western"><surname>Tao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Luo</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Nynrin preserves hematopoietic stem cell function by inhibiting the mitochondrial permeability transition pore opening</article-title><source>Cell Stem Cell</source><year>2024</year><volume>31</volume><issue>9</issue><fpage>1359</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.stem.2024.06.007</pub-id><pub-id pub-id-type="pmid">38955185</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Zhou C, Kuang M, Tao Y, Wang J, Luo Y, Fu Y, et al. Nynrin preserves hematopoietic stem cell function by inhibiting the mitochondrial permeability transition pore opening. Cell Stem Cell. 2024;31(9):1359&#8211;75. e8.<pub-id pub-id-type="pmid">38955185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.stem.2024.06.007</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>B</given-names></name><name name-style="western"><surname>Du</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>F</given-names></name><etal/></person-group><article-title>Developing a new sepsis screening tool based on lymphocyte count, international normalized ratio and procalcitonin (LIP score)</article-title><source>Sci Rep</source><year>2022</year><volume>12</volume><issue>1</issue><fpage>20002</fpage><pub-id pub-id-type="doi">10.1038/s41598-022-16744-9</pub-id><pub-id pub-id-type="pmid">36411279</pub-id><pub-id pub-id-type="pmcid">PMC9678875</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Liu B, Du H, Zhang J, Jiang J, Zhang X, He F, et al. Developing a new sepsis screening tool based on lymphocyte count, international normalized ratio and procalcitonin (LIP score). Sci Rep. 2022;12(1):20002.<pub-id pub-id-type="pmid">36411279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-022-16744-9</pub-id><pub-id pub-id-type="pmcid">PMC9678875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Jian</surname><given-names>W</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>B</given-names></name><name name-style="western"><surname>Liang</surname><given-names>L</given-names></name><etal/></person-group><article-title>The investigation of Nf&#954;b inhibitors to block cell proliferation in OSCC cells lines</article-title><source>Curr Med Chem</source><year>2025</year><volume>32</volume><issue>33</issue><fpage>7314</fpage><lpage>26</lpage><pub-id pub-id-type="doi">10.2174/0109298673309489240816063313</pub-id><pub-id pub-id-type="pmid">39192651</pub-id><pub-id pub-id-type="pmcid">PMC12645110</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Cheng Y, Wang L, Zhang S, Jian W, Zeng B, Liang L, et al. The investigation of Nf&#954;b inhibitors to block cell proliferation in OSCC cells lines. Curr Med Chem. 2025;32(33):7314&#8211;26.<pub-id pub-id-type="pmid">39192651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/0109298673309489240816063313</pub-id><pub-id pub-id-type="pmcid">PMC12645110</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>N</given-names></name></person-group><article-title>DNA extraction and polymerase chain reaction</article-title><source>J Cytol</source><year>2019</year><volume>36</volume><issue>2</issue><fpage>116</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4103/JOC.JOC_110_18</pub-id><pub-id pub-id-type="pmid">30992648</pub-id><pub-id pub-id-type="pmcid">PMC6425773</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Gupta N. DNA extraction and polymerase chain reaction. J Cytol. 2019;36(2):116&#8211;7.<pub-id pub-id-type="pmid">30992648</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4103/JOC.JOC_110_18</pub-id><pub-id pub-id-type="pmcid">PMC6425773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X-P</given-names></name><name name-style="western"><surname>Qu</surname><given-names>J</given-names></name><name name-style="western"><surname>Teng</surname><given-names>X-Q</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>H-H</given-names></name><name name-style="western"><surname>Dai</surname><given-names>Y-H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>The emerging role of super-enhancers as therapeutic targets in the digestive system tumors</article-title><source>Int J Biol Sci</source><year>2023</year><volume>19</volume><issue>4</issue><fpage>1036</fpage><pub-id pub-id-type="doi">10.7150/ijbs.78535</pub-id><pub-id pub-id-type="pmid">36923930</pub-id><pub-id pub-id-type="pmcid">PMC10008685</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Li X-P, Qu J, Teng X-Q, Zhuang H-H, Dai Y-H, Yang Z, et al. The emerging role of super-enhancers as therapeutic targets in the digestive system tumors. Int J Biol Sci. 2023;19(4):1036.<pub-id pub-id-type="pmid">36923930</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.7150/ijbs.78535</pub-id><pub-id pub-id-type="pmcid">PMC10008685</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rio</surname><given-names>DC</given-names></name><name name-style="western"><surname>Ares</surname><given-names>M</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Hannon</surname><given-names>GJ</given-names></name><name name-style="western"><surname>Nilsen</surname><given-names>TW</given-names></name></person-group><article-title>Purification of RNA using trizol (TRI reagent)</article-title><source>Cold Spring Harb Protoc</source><year>2010</year><pub-id pub-id-type="doi">10.1101/pdb.prot5439</pub-id><pub-id pub-id-type="pmid">20516177</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Rio DC, Ares M Jr, Hannon GJ, Nilsen TW. Purification of RNA using trizol (TRI reagent). Cold Spring Harb Protoc. 2010(6):pdb.prot5439 . 10.1101/pdb.prot5439.<pub-id pub-id-type="pmid">20516177</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1101/pdb.prot5439</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>C</given-names></name><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><etal/></person-group><article-title>Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer</article-title><source>Biol Direct</source><year>2024</year><volume>19</volume><issue>1</issue><fpage>65</fpage><pub-id pub-id-type="doi">10.1186/s13062-024-00518-6</pub-id><pub-id pub-id-type="pmid">39148138</pub-id><pub-id pub-id-type="pmcid">PMC11325698</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Liu Z, Sun L, Zhu W, Zhu J, Wu C, Peng X, et al. Disulfidptosis signature predicts immune microenvironment and prognosis of gastric cancer. Biol Direct. 2024;19(1):65.<pub-id pub-id-type="pmid">39148138</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13062-024-00518-6</pub-id><pub-id pub-id-type="pmcid">PMC11325698</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chandrashekar</surname><given-names>DS</given-names></name><name name-style="western"><surname>Bashel</surname><given-names>B</given-names></name><name name-style="western"><surname>Balasubramanya</surname><given-names>SAH</given-names></name><name name-style="western"><surname>Creighton</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Ponce-Rodriguez</surname><given-names>I</given-names></name><name name-style="western"><surname>Chakravarthi</surname><given-names>B</given-names></name><etal/></person-group><article-title>UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses</article-title><source>Neoplasia</source><year>2017</year><volume>19</volume><issue>8</issue><fpage>649</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.neo.2017.05.002</pub-id><pub-id pub-id-type="pmid">28732212</pub-id><pub-id pub-id-type="pmcid">PMC5516091</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Chandrashekar DS, Bashel B, Balasubramanya SAH, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. 2017;19(8):649&#8211;58.<pub-id pub-id-type="pmid">28732212</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.neo.2017.05.002</pub-id><pub-id pub-id-type="pmcid">PMC5516091</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Kang</surname><given-names>B</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name></person-group><article-title>GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses</article-title><source>Nucleic Acids Res</source><year>2017</year><volume>45</volume><issue>W1</issue><fpage>W98</fpage><lpage>102</lpage><pub-id pub-id-type="doi">10.1093/nar/gkx247</pub-id><pub-id pub-id-type="pmid">28407145</pub-id><pub-id pub-id-type="pmcid">PMC5570223</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98&#8211;102.<pub-id pub-id-type="pmid">28407145</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkx247</pub-id><pub-id pub-id-type="pmcid">PMC5570223</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thul</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Lindskog</surname><given-names>C</given-names></name></person-group><article-title>The human protein atlas: a spatial map of the human proteome</article-title><source>Protein Sci</source><year>2018</year><volume>27</volume><issue>1</issue><fpage>233</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1002/pro.3307</pub-id><pub-id pub-id-type="pmid">28940711</pub-id><pub-id pub-id-type="pmcid">PMC5734309</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Thul PJ, Lindskog C. The human protein atlas: a spatial map of the human proteome. Protein Sci. 2018;27(1):233&#8211;44.<pub-id pub-id-type="pmid">28940711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/pro.3307</pub-id><pub-id pub-id-type="pmcid">PMC5734309</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>G</given-names></name><name name-style="western"><surname>Cho</surname><given-names>M</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X</given-names></name></person-group><article-title>OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>50</volume><issue>D1</issue><fpage>D1334</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab970</pub-id><pub-id pub-id-type="pmid">34718715</pub-id><pub-id pub-id-type="pmcid">PMC8728272</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Tang G, Cho M, Wang X. OncoDB: an interactive online database for analysis of gene expression and viral infection in cancer. Nucleic Acids Res. 2022;50(D1):D1334-9.<pub-id pub-id-type="pmid">34718715</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkab970</pub-id><pub-id pub-id-type="pmcid">PMC8728272</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerami</surname><given-names>E</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J</given-names></name><name name-style="western"><surname>Dogrusoz</surname><given-names>U</given-names></name><name name-style="western"><surname>Gross</surname><given-names>BE</given-names></name><name name-style="western"><surname>Sumer</surname><given-names>SO</given-names></name><name name-style="western"><surname>Aksoy</surname><given-names>BA</given-names></name><etal/></person-group><article-title>The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data</article-title><source>Cancer Discov</source><year>2012</year><volume>2</volume><issue>5</issue><fpage>401</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmid">22588877</pub-id><pub-id pub-id-type="pmcid">PMC3956037</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401&#8211;4.<pub-id pub-id-type="pmid">22588877</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/2159-8290.CD-12-0095</pub-id><pub-id pub-id-type="pmcid">PMC3956037</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#225;nczky</surname><given-names>A</given-names></name><name name-style="western"><surname>Gy&#337;rffy</surname><given-names>B</given-names></name></person-group><article-title>Web-based survival analysis tool tailored for medical research (KMplot): development and implementation</article-title><source>J Med Internet Res</source><year>2021</year><volume>23</volume><issue>7</issue><fpage>27633</fpage><pub-id pub-id-type="doi">10.2196/27633</pub-id><pub-id pub-id-type="pmcid">PMC8367126</pub-id><pub-id pub-id-type="pmid">34309564</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">L&#225;nczky A, Gy&#337;rffy B. Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res. 2021;23(7):27633.<pub-id pub-id-type="doi" assigning-authority="pmc">10.2196/27633</pub-id><pub-id pub-id-type="pmcid">PMC8367126</pub-id><pub-id pub-id-type="pmid">34309564</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sherman</surname><given-names>BT</given-names></name><name name-style="western"><surname>Hao</surname><given-names>M</given-names></name><name name-style="western"><surname>Qiu</surname><given-names>J</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>X</given-names></name><name name-style="western"><surname>Baseler</surname><given-names>MW</given-names></name><name name-style="western"><surname>Lane</surname><given-names>HC</given-names></name><etal/></person-group><article-title>DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update)</article-title><source>Nucleic Acids Res</source><year>2022</year><volume>50</volume><issue>W1</issue><fpage>W216</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1093/nar/gkac194</pub-id><pub-id pub-id-type="pmid">35325185</pub-id><pub-id pub-id-type="pmcid">PMC9252805</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50(W1):W216-21.<pub-id pub-id-type="pmid">35325185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkac194</pub-id><pub-id pub-id-type="pmcid">PMC9252805</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wishart</surname><given-names>DS</given-names></name><name name-style="western"><surname>Knox</surname><given-names>C</given-names></name><name name-style="western"><surname>Guo</surname><given-names>AC</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>D</given-names></name><name name-style="western"><surname>Shrivastava</surname><given-names>S</given-names></name><name name-style="western"><surname>Tzur</surname><given-names>D</given-names></name><etal/></person-group><article-title>DrugBank: a knowledgebase for drugs, drug actions and drug targets</article-title><source>Nucleic Acids Res</source><year>2008</year><volume>36</volume><issue>Database issue</issue><fpage>29</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkm958</pub-id><pub-id pub-id-type="pmcid">PMC2238889</pub-id><pub-id pub-id-type="pmid">18048412</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, et al. DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008;36(Database issue):29.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/nar/gkm958</pub-id><pub-id pub-id-type="pmcid">PMC2238889</pub-id><pub-id pub-id-type="pmid">18048412</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>M</given-names></name><name name-style="western"><surname>Dai</surname><given-names>WT</given-names></name><name name-style="western"><surname>Hou</surname><given-names>MC</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>ZX</given-names></name><name name-style="western"><surname>Cao</surname><given-names>Y</given-names></name></person-group><article-title>CB-dock: a web server for cavity detection-guided protein-ligand blind docking</article-title><source>Acta Pharmacol Sin</source><year>2020</year><volume>41</volume><issue>1</issue><fpage>138</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1038/s41401-019-0228-6</pub-id><pub-id pub-id-type="pmid">31263275</pub-id><pub-id pub-id-type="pmcid">PMC7471403</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Liu Y, Grimm M, Dai WT, Hou MC, Xiao ZX, Cao Y. CB-dock: a web server for cavity detection-guided protein-ligand blind docking. Acta Pharmacol Sin. 2020;41(1):138&#8211;44.<pub-id pub-id-type="pmid">31263275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41401-019-0228-6</pub-id><pub-id pub-id-type="pmcid">PMC7471403</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fan</surname><given-names>G</given-names></name><name name-style="western"><surname>Tu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wu</surname><given-names>N</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>H</given-names></name></person-group><article-title>The expression profiles and prognostic values of HSPs family members in head and neck cancer</article-title><source>Cancer Cell Int</source><year>2020</year><volume>20</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1186/s12935-020-01296-7</pub-id><pub-id pub-id-type="pmid">32523426</pub-id><pub-id pub-id-type="pmcid">PMC7278206</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Fan G, Tu Y, Wu N, Xiao H. The expression profiles and prognostic values of HSPs family members in head and neck cancer. Cancer Cell Int. 2020;20:1&#8211;12.<pub-id pub-id-type="pmid">32523426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12935-020-01296-7</pub-id><pub-id pub-id-type="pmcid">PMC7278206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>C</given-names></name><name name-style="western"><surname>Xia</surname><given-names>Q</given-names></name><name name-style="western"><surname>Gu</surname><given-names>B</given-names></name><name name-style="western"><surname>Cui</surname><given-names>M</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>W</given-names></name><etal/></person-group><article-title>Esophageal cancer associated immune genes as biomarkers for predicting outcome in upper gastrointestinal tumors</article-title><source>Front Genet</source><year>2021</year><volume>12</volume><fpage>707299</fpage><pub-id pub-id-type="doi">10.3389/fgene.2021.707299</pub-id><pub-id pub-id-type="pmid">34349789</pub-id><pub-id pub-id-type="pmcid">PMC8327216</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Zhu C, Xia Q, Gu B, Cui M, Zhang X, Yan W, et al. Esophageal cancer associated immune genes as biomarkers for predicting outcome in upper gastrointestinal tumors. Front Genet. 2021;12:707299.<pub-id pub-id-type="pmid">34349789</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fgene.2021.707299</pub-id><pub-id pub-id-type="pmcid">PMC8327216</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Peng</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Luo</surname><given-names>C</given-names></name><name name-style="western"><surname>Sun</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><etal/></person-group><article-title>PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1</article-title><source>Front Immunol</source><year>2025</year><volume>16</volume><fpage>1581398</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2025.1581398</pub-id><pub-id pub-id-type="pmid">40534847</pub-id><pub-id pub-id-type="pmcid">PMC12174133</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Peng X, Liu Z, Luo C, Sun R, Zhang Y, Li B, et al. PSMD12 promotes hepatocellular carcinoma progression by stabilizing CDK1. Front Immunol. 2025;16:1581398.<pub-id pub-id-type="pmid">40534847</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2025.1581398</pub-id><pub-id pub-id-type="pmcid">PMC12174133</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>MM</given-names></name><name name-style="western"><surname>Califano</surname><given-names>JA</given-names></name></person-group><article-title>Molecular pathology of head-and&#8208;neck cancer</article-title><source>Int J Cancer</source><year>2004</year><volume>112</volume><issue>4</issue><fpage>545</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1002/ijc.20379</pub-id><pub-id pub-id-type="pmid">15382034</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Kim MM, Califano JA. Molecular pathology of head-and&#8208;neck cancer. Int J Cancer. 2004;112(4):545&#8211;53.<pub-id pub-id-type="pmid">15382034</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/ijc.20379</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Usman</surname><given-names>M</given-names></name><name name-style="western"><surname>Hameed</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Maryam</surname><given-names>A</given-names></name><name name-style="western"><surname>Mazhar</surname><given-names>A</given-names></name><etal/></person-group><article-title>SHMT2 is associated with tumor purity, CD8&#8201;+&#8201;T immune cells infiltration, and a novel therapeutic target in four different human cancers</article-title><source>Curr Mol Med</source><year>2023</year><volume>23</volume><issue>2</issue><fpage>161</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.2174/1566524022666220112142409</pub-id><pub-id pub-id-type="pmid">35023455</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Usman M, Hameed Y, Ahmad M, Iqbal MJ, Maryam A, Mazhar A, et al. SHMT2 is associated with tumor purity, CD8&#8201;+&#8201;T immune cells infiltration, and a novel therapeutic target in four different human cancers. Curr Mol Med. 2023;23(2):161&#8211;76.<pub-id pub-id-type="pmid">35023455</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1566524022666220112142409</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ahmad</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M</given-names></name><name name-style="western"><surname>Asif</surname><given-names>R</given-names></name><name name-style="western"><surname>Sial</surname><given-names>N</given-names></name><name name-style="western"><surname>Abid</surname><given-names>U</given-names></name><name name-style="western"><surname>Shamim</surname><given-names>T</given-names></name><etal/></person-group><article-title>Expression characteristics and significant diagnostic and prognostic values of ANLN in human cancers</article-title><source>Int J Gen Med</source><year>2022</year><pub-id pub-id-type="doi">10.2147/IJGM.S343975</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Ahmad M, Khan M, Asif R, Sial N, Abid U, Shamim T, et al. Expression characteristics and significant diagnostic and prognostic values of ANLN in human cancers. Int J Gen Med. 2022;15:1957&#8211;1972. 10.2147/IJGM.S343975.36389016
</mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Gao</surname><given-names>H</given-names></name><name name-style="western"><surname>Bijukchhe</surname><given-names>SM</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>T</given-names></name></person-group><article-title>PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer</article-title><source>Med Hypotheses</source><year>2013</year><volume>81</volume><issue>6</issue><fpage>1151</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.mehy.2013.09.022</pub-id><pub-id pub-id-type="pmid">24120699</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Li H, Gao H, Bijukchhe SM, Wang Y, Li T. PIAS3 may represent a potential biomarker for diagnosis and therapeutic of human colorectal cancer. Med Hypotheses. 2013;81(6):1151&#8211;4.<pub-id pub-id-type="pmid">24120699</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.mehy.2013.09.022</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Banerjee</surname><given-names>S</given-names></name></person-group><article-title>Differential PIAS3 expression in human malignancy</article-title><source>Oncol Rep</source><year>2004</year><volume>11</volume><issue>6</issue><fpage>1319</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">15138572</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Wang L, Banerjee S. Differential PIAS3 expression in human malignancy. Oncol Rep. 2004;11(6):1319&#8211;24.<pub-id pub-id-type="pmid">15138572</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabellino</surname><given-names>A</given-names></name><name name-style="western"><surname>Andreani</surname><given-names>C</given-names></name><name name-style="western"><surname>Scaglioni</surname><given-names>PP</given-names></name></person-group><article-title>The role of PIAS SUMO E3-ligases in cancer</article-title><source>Cancer Res</source><year>2017</year><volume>77</volume><issue>7</issue><fpage>1542</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-16-2958</pub-id><pub-id pub-id-type="pmid">28330929</pub-id><pub-id pub-id-type="pmcid">PMC5380518</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Rabellino A, Andreani C, Scaglioni PP. The role of PIAS SUMO E3-ligases in cancer. Cancer Res. 2017;77(7):1542&#8211;7.<pub-id pub-id-type="pmid">28330929</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-16-2958</pub-id><pub-id pub-id-type="pmcid">PMC5380518</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>H</given-names></name><name name-style="western"><surname>Umair</surname><given-names>M</given-names></name><name name-style="western"><surname>Khan</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sani</surname><given-names>AI</given-names></name><name name-style="western"><surname>Iqbal</surname><given-names>S</given-names></name><name name-style="western"><surname>Khalid</surname><given-names>F</given-names></name><etal/></person-group><article-title>CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology</article-title><source>Am J Transl Res</source><year>2024</year><volume>16</volume><issue>2</issue><fpage>432</fpage><pub-id pub-id-type="doi">10.62347/WSEF7878</pub-id><pub-id pub-id-type="pmid">38463578</pub-id><pub-id pub-id-type="pmcid">PMC10918119</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Hu H, Umair M, Khan SA, Sani AI, Iqbal S, Khalid F, et al. CDCA8, a mitosis-related gene, as a prospective pan-cancer biomarker: implications for survival prognosis and oncogenic immunology. Am J Transl Res. 2024;16(2):432.<pub-id pub-id-type="pmid">38463578</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.62347/WSEF7878</pub-id><pub-id pub-id-type="pmcid">PMC10918119</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luczak</surname><given-names>MW</given-names></name><name name-style="western"><surname>Jagodzi&#324;ski</surname><given-names>PP</given-names></name></person-group><article-title>The role of DNA methylation in cancer development</article-title><source>Folia Histochem Cytobiol</source><year>2006</year><volume>44</volume><issue>3</issue><fpage>143</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">16977793</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Luczak MW, Jagodzi&#324;ski PP. The role of DNA methylation in cancer development. Folia Histochem Cytobiol. 2006;44(3):143&#8211;54.<pub-id pub-id-type="pmid">16977793</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><mixed-citation publication-type="other">Taberlay PC, Jones PA. DNA methylation and cancer. In: Epigenetics and Disease: Pharmaceutical Opportunities. 2011. p. 1&#8211;23.</mixed-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Kulis M, Esteller M. DNA methylation and cancer. Adv Genet. 2010;70:27&#8211;56.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/B978-0-12-380866-0.60002-2</pub-id><pub-id pub-id-type="pmid">20920744</pub-id></mixed-citation></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abdel-Maksoud</surname><given-names>MA</given-names></name><name name-style="western"><surname>Ullah</surname><given-names>S</given-names></name><name name-style="western"><surname>Nadeem</surname><given-names>A</given-names></name><name name-style="western"><surname>Shaikh</surname><given-names>A</given-names></name><name name-style="western"><surname>Zia</surname><given-names>MK</given-names></name><name name-style="western"><surname>Zakri</surname><given-names>AM</given-names></name><etal/></person-group><article-title>Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis</article-title><source>Am J Translational Res</source><year>2024</year><volume>16</volume><issue>1</issue><fpage>63</fpage><pub-id pub-id-type="doi">10.62347/TWOY1681</pub-id><pub-id pub-id-type="pmcid">PMC10839381</pub-id><pub-id pub-id-type="pmid">38322551</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Abdel-Maksoud MA, Ullah S, Nadeem A, Shaikh A, Zia MK, Zakri AM, et al. Unlocking the diagnostic, prognostic roles, and immune implications of BAX gene expression in pan-cancer analysis. Am J Translational Res. 2024;16(1):63.<pub-id pub-id-type="doi" assigning-authority="pmc">10.62347/TWOY1681</pub-id><pub-id pub-id-type="pmcid">PMC10839381</pub-id><pub-id pub-id-type="pmid">38322551</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agboola</surname><given-names>A</given-names></name><name name-style="western"><surname>Musa</surname><given-names>A</given-names></name><name name-style="western"><surname>Banjo</surname><given-names>A</given-names></name><name name-style="western"><surname>Ayoade</surname><given-names>B</given-names></name><name name-style="western"><surname>Deji-Agboola</surname><given-names>M</given-names></name><name name-style="western"><surname>Nolan</surname><given-names>C</given-names></name><etal/></person-group><article-title>Pias&#947; expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women</article-title><source>J Clin Pathol</source><year>2013</year><pub-id pub-id-type="doi">10.1136/jclinpath-2013-201658</pub-id><pub-id pub-id-type="pmid">24170211</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Agboola A, Musa A, Banjo A, Ayoade B, Deji-Agboola M, Nolan C, et al. Pias&#947; expression in relation to clinicopathological, tumour factors and survival in indigenous black breast cancer women. J Clin Pathol. 2013. 10.1136/jclinpath-2013-201658.<pub-id pub-id-type="pmid">24170211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/jclinpath-2013-201658</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stein</surname><given-names>U</given-names></name><name name-style="western"><surname>Burock</surname><given-names>S</given-names></name><name name-style="western"><surname>Herrmann</surname><given-names>P</given-names></name><name name-style="western"><surname>Wendler</surname><given-names>I</given-names></name><name name-style="western"><surname>Niederstrasser</surname><given-names>M</given-names></name><name name-style="western"><surname>Wernecke</surname><given-names>K-D</given-names></name><etal/></person-group><article-title>Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients</article-title><source>J Mol Diagn</source><year>2011</year><volume>13</volume><issue>2</issue><fpage>189</fpage><lpage>98</lpage><pub-id pub-id-type="doi">10.1016/j.jmoldx.2010.10.002</pub-id><pub-id pub-id-type="pmid">21354054</pub-id><pub-id pub-id-type="pmcid">PMC3128604</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Stein U, Burock S, Herrmann P, Wendler I, Niederstrasser M, Wernecke K-D, et al. Diagnostic and prognostic value of metastasis inducer S100A4 transcripts in plasma of colon, rectal, and gastric cancer patients. J Mol Diagn. 2011;13(2):189&#8211;98.<pub-id pub-id-type="pmid">21354054</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jmoldx.2010.10.002</pub-id><pub-id pub-id-type="pmcid">PMC3128604</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Chu</surname><given-names>M</given-names></name></person-group><article-title>Advances in immunosuppressive agents based on signal pathway</article-title><source>Front Pharmacol</source><year>2022</year><volume>13</volume><fpage>917162</fpage><pub-id pub-id-type="doi">10.3389/fphar.2022.917162</pub-id><pub-id pub-id-type="pmid">35694243</pub-id><pub-id pub-id-type="pmcid">PMC9178660</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Xu Z, Chu M. Advances in immunosuppressive agents based on signal pathway. Front Pharmacol. 2022;13:917162.<pub-id pub-id-type="pmid">35694243</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2022.917162</pub-id><pub-id pub-id-type="pmcid">PMC9178660</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>D</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>C</given-names></name></person-group><article-title>Identification of key genes and molecular pathways in keratoconus: integrating text mining and bioinformatics analysis</article-title><source>Biomed Res Int</source><year>2022</year><pub-id pub-id-type="doi">10.1155/2022/4740141</pub-id><pub-id pub-id-type="pmid">36051483</pub-id><pub-id pub-id-type="pmcid">PMC9427295</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Hu D, Lin Z, Jiang J, Li P, Zhang Z, Yang C. Identification of key genes and molecular pathways in keratoconus: integrating text mining and bioinformatics analysis. Biomed Res Int. 2022. 10.1155/2022/4740141.<pub-id pub-id-type="pmid">36051483</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2022/4740141</pub-id><pub-id pub-id-type="pmcid">PMC9427295</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kesarwani</surname><given-names>P</given-names></name><name name-style="western"><surname>Murali</surname><given-names>AK</given-names></name><name name-style="western"><surname>Al-Khami</surname><given-names>AA</given-names></name><name name-style="western"><surname>Mehrotra</surname><given-names>S</given-names></name></person-group><article-title>Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease</article-title><source>Antioxid Redox Signal</source><year>2013</year><volume>18</volume><issue>12</issue><fpage>1497</fpage><lpage>534</lpage><pub-id pub-id-type="doi">10.1089/ars.2011.4073</pub-id><pub-id pub-id-type="pmid">22938635</pub-id><pub-id pub-id-type="pmcid">PMC3603502</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Kesarwani P, Murali AK, Al-Khami AA, Mehrotra S. Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal. 2013;18(12):1497&#8211;534.<pub-id pub-id-type="pmid">22938635</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/ars.2011.4073</pub-id><pub-id pub-id-type="pmcid">PMC3603502</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J</given-names></name><name name-style="western"><surname>Guo</surname><given-names>S</given-names></name><etal/></person-group><article-title>Integrated bioinformatics analysis reveals potential mechanisms associated with intestinal flora intervention in nonalcoholic fatty liver disease</article-title><source>Medicine</source><year>2022</year><volume>101</volume><issue>36</issue><fpage>e30184</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000030184</pub-id><pub-id pub-id-type="pmid">36086766</pub-id><pub-id pub-id-type="pmcid">PMC10980383</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Liu Y, Liu X, Zhou W, Zhang J, Wu J, Guo S, et al. Integrated bioinformatics analysis reveals potential mechanisms associated with intestinal flora intervention in nonalcoholic fatty liver disease. Medicine. 2022;101(36):e30184.<pub-id pub-id-type="pmid">36086766</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MD.0000000000030184</pub-id><pub-id pub-id-type="pmcid">PMC10980383</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sial</surname><given-names>N</given-names></name><name name-style="western"><surname>Rehman</surname><given-names>JU</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>S</given-names></name><name name-style="western"><surname>Ahmad</surname><given-names>M</given-names></name><name name-style="western"><surname>Hameed</surname><given-names>Y</given-names></name><name name-style="western"><surname>Atif</surname><given-names>M</given-names></name><etal/></person-group><article-title>Integrative analysis reveals methylenetetrahydrofolate dehydrogenase 1-like as an independent shared diagnostic and prognostic biomarker in five different human cancers</article-title><source>Biosci Rep</source><year>2022</year><pub-id pub-id-type="doi">10.1042/BSR20211783</pub-id><pub-id pub-id-type="pmid">34908119</pub-id><pub-id pub-id-type="pmcid">PMC8738869</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Sial N, Rehman JU, Saeed S, Ahmad M, Hameed Y, Atif M, et al. Integrative analysis reveals methylenetetrahydrofolate dehydrogenase 1-like as an independent shared diagnostic and prognostic biomarker in five different human cancers. Biosci Rep. 2022. 10.1042/BSR20211783.<pub-id pub-id-type="pmid">34908119</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/BSR20211783</pub-id><pub-id pub-id-type="pmcid">PMC8738869</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>K</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>B</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X</given-names></name></person-group><article-title>The impact of dysregulation SUMOylation on prostate cancer</article-title><source>J Transl Med</source><year>2025</year><volume>23</volume><issue>1</issue><fpage>286</fpage><pub-id pub-id-type="doi">10.1186/s12967-025-06271-2</pub-id><pub-id pub-id-type="pmid">40050932</pub-id><pub-id pub-id-type="pmcid">PMC11887156</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Li K, Wang H, Jiang B, Jin X. The impact of dysregulation SUMOylation on prostate cancer. J Transl Med. 2025;23(1):286.<pub-id pub-id-type="pmid">40050932</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12967-025-06271-2</pub-id><pub-id pub-id-type="pmcid">PMC11887156</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Heppler</surname><given-names>LN</given-names></name><name name-style="western"><surname>Frank</surname><given-names>DA</given-names></name></person-group><article-title>Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors</article-title><source>Trends Cancer</source><year>2017</year><volume>3</volume><issue>12</issue><fpage>816</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.trecan.2017.10.004</pub-id><pub-id pub-id-type="pmid">29198438</pub-id><pub-id pub-id-type="pmcid">PMC5727919</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Heppler LN, Frank DA. Targeting oncogenic transcription factors: therapeutic implications of endogenous STAT inhibitors. Trends Cancer. 2017;3(12):816&#8211;27.<pub-id pub-id-type="pmid">29198438</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.trecan.2017.10.004</pub-id><pub-id pub-id-type="pmcid">PMC5727919</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hua</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Meng</surname><given-names>D</given-names></name><name name-style="western"><surname>Gan</surname><given-names>R</given-names></name><name name-style="western"><surname>Chen</surname><given-names>N</given-names></name><name name-style="western"><surname>He</surname><given-names>L</given-names></name><etal/></person-group><article-title>CTSG restraines the proliferation and metastasis of head and neck squamous cell carcinoma by blocking the JAK2/STAT3 pathway</article-title><source>Cell Signal</source><year>2025</year><volume>127</volume><fpage>111562</fpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2024.111562</pub-id><pub-id pub-id-type="pmid">39672353</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Hua H, Yang X, Meng D, Gan R, Chen N, He L, et al. CTSG restraines the proliferation and metastasis of head and neck squamous cell carcinoma by blocking the JAK2/STAT3 pathway. Cell Signal. 2025;127:111562.<pub-id pub-id-type="pmid">39672353</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cellsig.2024.111562</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ning</surname><given-names>Q</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T</given-names></name><name name-style="western"><surname>Guo</surname><given-names>X</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>M</given-names></name><etal/></person-group><article-title>CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes</article-title><source>J Viral Hepat</source><year>2023</year><volume>30</volume><issue>12</issue><fpage>951</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/jvh.13886</pub-id><pub-id pub-id-type="pmid">37735836</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Ning Q, Yang T, Guo X, Huang Y, Gao Y, Liu M, et al. CHB patients with rtA181T-mutated HBV infection are associated with higher risk hepatocellular carcinoma due to increases in mutation rates of tumour suppressor genes. J Viral Hepat. 2023;30(12):951&#8211;8.<pub-id pub-id-type="pmid">37735836</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jvh.13886</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>B</given-names></name><name name-style="western"><surname>Rasul</surname><given-names>A</given-names></name><name name-style="western"><surname>Qin</surname><given-names>H</given-names></name><name name-style="western"><surname>Li</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>X</given-names></name></person-group><article-title>PIAS1-modulated Smad2/4 complex activation is involved in zinc-induced cancer cell apoptosis</article-title><source>Cell Death Dis</source><year>2013</year><volume>4</volume><issue>9</issue><fpage>e811-e</fpage><pub-id pub-id-type="doi">10.1038/cddis.2013.333</pub-id><pub-id pub-id-type="pmid">24052079</pub-id><pub-id pub-id-type="pmcid">PMC3789191</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Yang N, Zhao B, Rasul A, Qin H, Li J, Li X. PIAS1-modulated Smad2/4 complex activation is involved in zinc-induced cancer cell apoptosis. Cell Death Dis. 2013;4(9):e811-e.<pub-id pub-id-type="pmid">24052079</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/cddis.2013.333</pub-id><pub-id pub-id-type="pmcid">PMC3789191</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mihalas</surname><given-names>AB</given-names></name><name name-style="western"><surname>Arora</surname><given-names>S</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>SA</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>HM</given-names></name><name name-style="western"><surname>Cucinotta</surname><given-names>CE</given-names></name><name name-style="western"><surname>Mitchell</surname><given-names>K</given-names></name><etal/></person-group><article-title>KAT5 regulates neurodevelopmental states associated with G0-like populations in glioblastoma</article-title><source>Nat Commun</source><year>2025</year><volume>16</volume><issue>1</issue><fpage>1</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1038/s41467-025-59503-w</pub-id><pub-id pub-id-type="pmid">40346033</pub-id><pub-id pub-id-type="pmcid">PMC12064679</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Mihalas AB, Arora S, O&#8217;Connor SA, Feldman HM, Cucinotta CE, Mitchell K, et al. KAT5 regulates neurodevelopmental states associated with G0-like populations in glioblastoma. Nat Commun. 2025;16(1):1&#8211;20.<pub-id pub-id-type="pmid">40346033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41467-025-59503-w</pub-id><pub-id pub-id-type="pmcid">PMC12064679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zang</surname><given-names>X</given-names></name><name name-style="western"><surname>He</surname><given-names>X-Y</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>C-M</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M-Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C-Y</given-names></name><etal/></person-group><article-title>Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between sumoylation and phosphorylation of STAT1</article-title><source>Mol Cancer</source><year>2024</year><volume>23</volume><issue>1</issue><fpage>207</fpage><pub-id pub-id-type="doi">10.1186/s12943-024-02124-6</pub-id><pub-id pub-id-type="pmid">39334380</pub-id><pub-id pub-id-type="pmcid">PMC11438063</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Zang X, He X-Y, Xiao C-M, Lin Q, Wang M-Y, Liu C-Y, et al. Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between sumoylation and phosphorylation of STAT1. Mol Cancer. 2024;23(1):207.<pub-id pub-id-type="pmid">39334380</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s12943-024-02124-6</pub-id><pub-id pub-id-type="pmcid">PMC11438063</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>R</given-names></name><name name-style="western"><surname>Ford</surname><given-names>CA</given-names></name><name name-style="western"><surname>Rodgers</surname><given-names>L</given-names></name><name name-style="western"><surname>Rushworth</surname><given-names>LK</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>J</given-names></name><name name-style="western"><surname>Mui</surname><given-names>E</given-names></name><etal/></person-group><article-title>Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression</article-title><source>Cancer Res</source><year>2022</year><volume>82</volume><issue>14</issue><fpage>2565</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-21-1301</pub-id><pub-id pub-id-type="pmid">35675421</pub-id><pub-id pub-id-type="pmcid">PMC9381098</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Patel R, Ford CA, Rodgers L, Rushworth LK, Fleming J, Mui E, et al. Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression. Cancer Res. 2022;82(14):2565&#8211;75.<pub-id pub-id-type="pmid">35675421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1158/0008-5472.CAN-21-1301</pub-id><pub-id pub-id-type="pmcid">PMC9381098</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Iwamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>P</given-names></name><name name-style="western"><surname>Agrawal</surname><given-names>NG</given-names></name><name name-style="western"><surname>Rubin</surname><given-names>EH</given-names></name><name name-style="western"><surname>Wagner</surname><given-names>JA</given-names></name></person-group><article-title>Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor</article-title><source>Cancer Chemother Pharmacol</source><year>2013</year><volume>72</volume><fpage>493</fpage><lpage>508</lpage><pub-id pub-id-type="doi">10.1007/s00280-013-2220-z</pub-id><pub-id pub-id-type="pmid">23820962</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Iwamoto M, Friedman EJ, Sandhu P, Agrawal NG, Rubin EH, Wagner JA. Clinical pharmacology profile of vorinostat, a histone deacetylase inhibitor. Cancer Chemother Pharmacol. 2013;72:493&#8211;508.<pub-id pub-id-type="pmid">23820962</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00280-013-2220-z</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>